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Abstracts
  There is growing interest in multi-regional clinical trials (MRCTs), 
which are those conducted in many regions using the common 
protocol. MRCTs simplify the approval and registration processes for 
treatment in all regions, and provide an opportunity to reduce costs 
and time consumption by not repeating similar clinical trials. 
Accomplishing the goal of MRCTs depends on consistency in the effect 
size of individual regions following verification of overall treatment 
effects. However, there are currently no criteria to assess the 
similarity of treatment effects across regions, or standards for 
calculating the required number of clinical trial subjects in the region 
of interest to demonstrate such similarity. In 2007, Japanese MHLW 
provided guideline on similarity criteria and the required number of 
clinical trial subjects in Japan for MRCTs. However, this guideline does 
not offer a statistical perspective.
  Based on the MHLW guideline, Ko et al. (2010) proposed a method 
based on the concept of the assurance probability to calculate the 
sample size in the region of interest. But this method does not focus 
on the second purpose of MRCTs, which concerns the similarity of 
treatment effects across regions. This thesis introduces a method 
standardized by effect size, which was originally suggested by Kang et 
al. (2016), as a statistical hypothesis testing procedure to address the 
second purpose of MRCTs. This thesis also discusses approaches using 
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the regional type II error rate to calculate critical values for a 
hypothesis testing on the similarity, as well as the required number of 
clinical trial subjects in the region of interest through the suggested 
method. 
  Using calculated regional type II error rates according to similarity 
criteria, it was shown that it is easier to control the regional type II 
error rate if the difference in effect sizes between the region of 
interest and other regions excluding the region of interest is great or 
the critical value for the similarity increases. If a pre-determined 
regional type II error rate is satisfied and parameters such as effect 
size and the required number of patients in the region of interest are 
the same respectively, the critical value for the similarity criterion 
 ≥  is considered more conservative compared to the critical 
value for the similarity criterion  ≥  . The proportion of the 
patients in the region of interest did not monotonically decrease with 
the regional type II error rate. Such an undesirable property needs to 
be improved by developing new similarity criteria. Furthermore, the 
method used to control the regional type I error rate is an expanded 
form of the method proposed by Ko et al. (2010), in the sense that it 
is applicable in cases where the effect sizes across regions are 
heterogeneous. 
  Recently, there has been an increasing trend of globalization in 
developing new drugs using MRCTs in Korea. As the frequency of 
conducting MRCTs increases, it has become important to determine 
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Key words : Multi-regional clinical trial, Similarity criteria, Critical value, 
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critical value to evaluate the similarity in treatment effects between 
ethnic groups and to calculate the sample size in the region of 
interest, such as Korea. In such clinical development environments, 
the regional type II error method proposed in this thesis will be useful 
for MRCTs, and should be further studied for continued improvement.
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Chapter 1. Introduction
  Korea has a short history of new drug development compared to 
economically developed countries such as the United States (US), 
European countries, and Japan. Therefore, the infrastructure for 
clinical trials was inadequate compared to such countries until the 
1990s. However, globalization of new drug clinical trials since 2000 
increased the number of clinical trials in Korea to 202 cases in 2009. 
Korea is ranked as the 12th country and Seoul the 3rd city in clinical 
trial participation in the world (Bae, 2010). 
  According th the '2015 Clinical trial Protocol Approval Status and 
Annual Inspection Result Presentation' published in 2016 by the 
Ministry of Food and Drug Safety, the approved clinical trials in Korea 
is continuously increasing from 503 cases in 2011 to 652 cases in 
2014. In addition, the number of clinical trials including multi-regional 
clinical trials (MRCTs) in 2015 was 675 cases, which is a 3.5% annual 
increase compared to 652 cases in 2014. A comparison of Korean and 
multi-national pharmaceutical companies showed a greater number of 
approvals for multi-national companies by 55% to 45% in 2015. 
Confirmatory clinical trials, phase III clinical trials, accounted for 58% 
of approved clinical trials in multi-national pharmaceutical companies  
(MFDS, 2016). Due to the increase in drug clinical trials in Korea and 
globalization of development of drugs, it has become essential to 
establish developing strategies to explain variances in the intrinsic 
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(e.g.; genetic, physiological) and extrinsic (e.g.: medical practice, 
cultural and environmental) characteristic of participating regions on 
the efficacy and safety of developing products.
  In 1998, the International Conference on Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
announced a guideline entitled “Ethnic Factors in the Acceptability of 
Foreign Clinical Data". The ICH E5 guideline proposed a bridging study 
to produce additional information for utilization of foreign clinical data 
when this data fails to provide sufficient bridging evidence. Korea 
acted upon the ICH E5 guideline until the mid-2000s and utilized a 
bridging strategy that required a bridging study for new foreign drug 
approval, in order to identify intrinsic and extrinsic difference between 
ethnicities exposed to the drug. The ICH guideline defines a bridging 
study as follow: "Bridging study is a supplementary study conducted to 
allow extrapolation of foreign clinical data on the population of the 
new region in order to provide pharmacodynamic or clinical data on 
efficacy, safety, dosage and dose regimen of the drug". However, a 
bridging strategy is an additional strategy conducted by the country of 
interest, which involves a bridging study with the aim to utilize all 
clinical data from the country of origin. The strategy is conducted on 
products after the required phase I, II and III clinical trials and the 
drug approval are completed in the country of origin. Although the 
bridging study, conducted for a bridging strategy as suggested by ICH 
E5 guideline, provides regulatory strategies to minimize overlap in 
clinical trials, the need for valuable resources for duplication of large 
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clinical trials in all regions is inevitable. Furthermore, the bridging 
study conducted for bridging strategy has an issue similar to the 
phenomenon known as "Drug lag". This describes the fact that a new 
country cannot release a drug until a few years after its release in 
countries including the country of origin, thus reducing the product 
lifetime and delaying the provision of new treatments to patients in 
that new country.
  Recently, many global pharmaceutical companies have been involved 
in drug development through MRCTs to overcome the problems 
discussed above. In a study by Ando et al. (2010) in which cases of 
MRCTs were introduced, the trial includes various study design with 
different countries and ethnicities. MRCTs conducted with bridging 
purposes in the context of a global development program should not 
only simplify the approval and registration of new drugs in all regions 
but also provide an opportunity to reduce time consumption and costs 
from conducting repetitive clinical trials. Such merit has led to 
continuous interest in MRCTs. The 11th ICH E5 Q&A describes an 
MRCT as a study that uses a common protocol in more than one 
region for bridging that allows near simultaneous worldwide 
registration and thus can be conducted in the context of a global 
development program.  
  The objective of MRCTs should therefore be to show that the drug 
is effective in the region and to compare the results of the study 
between the regions with the intent of establishing that the drug is 
not sensitive to ethnic factors. A closer look at the statements in the 
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ICH E5 guideline states that in an MRCT planning, sufficient numbers 
of patients, with adequate power to show treatment effect should be 
registered in each region. The guideline further emphasize that the 
ability of MRCTs to achieve their purpose depends on “the extent of 
similarity in drug effects between individual participating regions”. 
However, there are no detailed suggestions on definitions for 
treatment effects such as “not sensitive”, “similar” or “consistent”, or 
sample size determination of participating individual regions. These 
depend on scientific aspects and regulatory requirements which may 
vary from region to region.  
  It could be argued that the design and analysis of MRCTs are 
similar to those of multi-center clinical trials. The reason may be that 
in both cases data are collected from multiple units, such as centers 
or regions, and intended to be analyzed as a whole, where 
heterogeneity of the treatment effect across units may exist. However, 
the crucial difference is that in multi-center clinical trials one 
regulatory agency reviews the material and decides on market release 
in the country, whereas in MRCTs, there is no such thing as “Global 
approval”. In other words, the significance of the overall results does 
not guarantee market approval in each country. Therefore, in extreme 
cases, the same MRCT material can be interpreted differently by 
regulatory bodies of each region to arrive at different conclusions. In 
general, in order to investigate the existence of heterogeneity 
according to center or region, a method to confirm the existence of 
treatment-by-center or treatment-by-region interaction is used. 
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According to Chen et al. (2010), in recently published MRCTs, 
treatment-by-region interaction tests are commonly used to assess 
heterogeneous treatment effect across regions and a non-significant 
interaction test would lead to the conclusion that the treatment effect 
is consistent across regions. 
  If individual center results in cases that use interaction tests show 
extreme or opposite results between centers, the results should be 
discussed. The Q&A for the ICH E9 guideline states that there should 
be at least 10 patients in each center. Shao and Chow (1993) argued 
that this number should not be less that the number of centers. 
These proposals focus on investigation treatment-by-center 
interactions and the resulting sample sizes may not be adequate to 
show the efficacy of a new drug in an individual region, as required 
in an MRCT. In addition, to evaluate the interaction effects, a very 
large sample size is needed, and the numbers involved can make it 
unrealistic to conduct a trial.
  There are currently no statistical criteria provided by the ICH E5 
guideline to assess the treatment similarity or consistency between 
overall clinical data and data from the region of interest. Moreover, 
until 2007 no regulatory agency in any country provided guidelines on 
the required number of patients for allocation in the region of interest 
to assess the similarity in treatment effects across regions. The first 
standard to assess such similarities was suggested in September 2007 
by the Japanese Ministry of Health, Labor, and Welfare (MHLW) 
through the publication of a guideline called "The Basic Principles on 
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Global Clinical Trials". This guideline, similar to ICH E5, describes 
MRCTs as planned research conducted in medical institutions in 
numerous countries with a common protocol for the purpose of the 
development and approval of new drugs. This guideline provides 
detailed questions on consideration of the required number of 
Japanese patients, a description of basic concepts and an introduction 
for conducting MRCTs in a Q&A format. 
  The guideline also provides two methods to decide on the number of 
Japanese subjects required to obtain identical results from the 
participating Japanese patients compared to overall patient data in 
MRCTs. Let  be the observed difference between the effects of 
placebo and the drug in patient groups in all regions, whereas  is 
the observed difference in the Japanese patient group. The first 
method in the guideline, 'Method 1' for shot, requires that the number 
of Japanese patients is sufficiently large to ensure  with a 
probability of at least 80%, where  is a pre-specified threshold and 
≥ is generally recommended. The second method in the guideline, 
'Method 2' for short, requires that the sample size is sufficiently large 
to demonstrate a consistent trend for all individual regions. For 
example, assume that three regions participated in a global clinical 
trial and let ,  and  denote the observed treatment differences. 
Then the number of clinical trial subjects is determined such that 
each individual difference ,  and  is larger than 0 with a 
probability of at least 80%. 
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  Kawai et al. (2008) discussed Method 2 and proposed an approach to 
rationalize partitioning the total sample size among the regions so that 
a high probability of observing a consistent trend under the assumed 
treatment effect across regions can be derived if the treatment effect 
is positive and uniform across regions in a confirmatory MRCT. Their 
approach takes an overall perspective in that its main purpose is to 
estimate the overall treatment effect. On the other hand, Ko et al. 
(2010) discussed Method 1 taking a regional viewpoint and focused on 
estimating the treatment effect in a specific region. Specifically, they 
proposed a method for calculating sample size in the specific region 
in order to ensure that the assurance probabilities for similarity 
criteria under the alternative hypothesis for the primary purpose of 
MRCTs were maintained at a desired level, say, 80%. However, as 
mentioned above, MRCTs have two purposes. First, there is a need to 
prove significance of the new drug compared to placebo in the overall 
clinical trial subject group. Second, there is a need to prove treatment 
effects are the similarity in patients in the region of interest and the 
overall patient group. The two purposes result in different hypotheses. 
The first purpose is related to the overall treatment effects of the 
clinical trial and the primary hypothesis of an MRCT is established 
based on the first purpose. The second purpose is to assess 
consistency of the treatment effect across regions, resulting in the 
secondary hypothesis. Ko et al. (2010) evaluated the assurance 
probabilities on similarity criteria under the primary alternative 
hypothesis. The purpose of the assurance probabilities is to assess the 
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consistency of treatment effects across regions, following the 
evaluation of overall treatment effect results. Kang et al. (2016) 
emphasizes the fact that the assurance probabilities should be 
assessed via the secondary alternative hypothesis, not the first. 
  This thesis will focus on the two purposes of MRCTs to discuss the 
critical values for assessing the similarity and to calculating the 
sample size in the region of interest using Method 1. Using the 
method by Kang et al. (2016), a standardized equation on effect size 
will be suggested and a comparison with the assurance probability by 
Ko et al. (2010) will be conducted. If the difference in treatment 
effects between the region of interest and other regions excluding the 
region of interest is predicted to be significant in the design stage, the 
similarity criteria of Method 1 cannot be used and an independent 
clinical trial needs to be conducted on the region of interest. 
However, such difference in effects cannot be distinctively defined and 
thus in the design stage of this study, both cases with significant and 
insignificant differences in treatment effects between patients in the 
region of interest and other regions excluding the region of interest 
will be included. This will be done using the similarity criteria 
discussed above for calculating the required number of clinical trial 
subjects. For the assumed treatment effects, results from the US Food 
and Drug Administration (FDA) Statistical Review on approved drugs 
from 2011 to 2014 will be used. 
  The contents of this thesis are as follows. Chapter 2 will discuss the 
similarity criteria proposed by Japan’s MHLW, which can be evaluated 
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to consider similar treatment effects between the region of interest 
and all regions in MRCTs, as well as the similarity criteria by Ko et al. 
(2010). Chapter 3 will examine the assurance probabilities proposed by 
Ko et al. (2010). In chapter 4, we will examine the assurance 
probabilities using the regional type II error rate as suggested by Kang 
et al. (2016) and propose a standardized method. A literature review 
on effect size will be suggested to standardize and utilize the method 
suggested by Kang et al. (2016). Chapter 5 will discuss the calculated 
results of  regional type II error rates and regional type I error rates 
according to the effect size. We will also discuss the method for 
choosing critical values  and  according to the effect size and 
results. Chapters 6 and 7 will discuss examples in real clinical trial 
conditions, followed by a discussion and conclusion. 
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Chapter 2. Similarity criteria
The first purpose of MRCTs is to determine the treatment effects in 
all participating regions, and the second purpose is to assess 
applicability of the overall clinical trial results to each region. In order 
to assess the second purpose, similarity criteria to confirm 
applicability of the trial results in the region of interest is important.
This section will discuss such similarity criteria. For the sake of 
simplicity, this thesis only deals with a phase III confirmatory clinical 
trial that utilizes parallel group design to compare a new treatment 
group and placebo group.  
  The notation used in this thesis to explain the similarity criteria will 
be described. Continuous primary endpoints that represent efficacy 
results are denoted as  and , each in regard to patients given new 
treatment and placebo, respectively. The greater the difference in the 
primary endpoints between the new treatment and placebo groups will 
be defined to have greater treatment effects.   
 ∼  
     ∼  

where the population variance  is assumed to be known, although 
is actually unknown and must be estimated from actual clinical trial 
data.  
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  Let  and  be the population means of the new treatment and 
placebo, respectively, and let the overall treatment difference be 
∆    . 
  The hypothesis of the first purpose of the MRCT for testing the 
overall treatment effect is shown below.
                      ∆ ≤     ∆                    (1)
The primary hypothesis states that the new treatment is effective at a 
global level. Although the primary hypothesis is the one sided 
hypothesis to test the overall treatment effect, the methods proposed 
by Ko et al. (2010) and Kang et al. (2016) can be straightforwardly 
extended to the two-sided hypothesis. 
  Let  denote the total number of patients planned for the trial, 
divided equally between the new treatment group and the placebo 
control group (ie, equally allocation of subjects to the treatment 
group). If the total sample size for the each group  is for a 
one-sided test with the desired significant level  and power  for 
detecting an expected overall difference ∆, then the equation for 
the sample size calculation is as follows.
 
  

                       (2)
where  is the th percentile of the standard normal 
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distribution (Chow et al., 2003).
  Let  be the number of regions participating in the MRCT and 
refers to the proportion of patients in ith participating region from the 
total number of subjects , resulting in   ⋯,     . 
Furthermore, let     be the number of patients assigned to each 
treatment group from the ith participating region. Random variables 
and  refer to the primary endpoints representing treatment effects 
in the jth or rth patient given the new treatment or the placebo from 
the ith participating region.
  Without a loss of generality, assume that the region of interest is 
the first region and thus    region. Let  be the mean difference 
in observed effects between new treatment and placebo groups for the 
first region. Let  denote the mean difference in observed effects for 
all regions. Let  be the mean difference in observed effects for 
regions other than the first region. Hence,
 
 
     
 


  


  
    
 


  


  
   (3)
where
  


  

    
  


  


In addition,  is the test statistic for the first region,  is the test 
statistic for all regions and  is the test statistic for regions other 
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than the first region. That is,   
 




 

    


 


  

 
    

 


  

 
  (4)
   
  We will focus on the two similarity criteria suggested by Ko et al.  
(2010) in order to assess consistency of treatment effects under the 
condition that the overall treatment effect is significant at the 
significance level .
(ⅰ)  ≥   for some     
(ⅱ)  ≥   for some     
Here, the first similarity criterion is that the extent of the treatment 
effect of the new treatment in the first region has to be similar to the 
treatment effect in regions other than the first region. The second 
criterion is that the extent of the treatment effect of the new 
treatment in the first region has to be similar to the treatment effect 
in all participating regions. In particular, Japanese MHLW suggested 
using the second criterion, so that the treatment effect between the 
first region (Japan) and all populations can be consistent when the 
ratio of treatment effect estimate for the first region to that for the 
overall population is greater than , that is,  ≥  with  ≥ 
(MHLW, 2007).   
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Chapter 3. Assurance probability
3.1. Assurance probability of similarity by Ko et al. 
  Ko et al. (2010) proposed a method to determine the proportion of 
patients out of 2 in the first region  in the overall significance 
level , using the assurance probability on similarity criteria (i) and 
(ii), when the expected difference in overall treatment effect is ∆  . 
When the overall treatment effect is ∆  , under the assumption that 
the treatment effect of the new treatment and placebo is uniform 
across regions, the assurance probability for the first similarity 
criterion (i) denoted as  can be expressed as below. 
   ≥     



∞

  
 
  

             (5)
where  is the probability measure with respect to ∆   and
  

 

                    
    and      
  
and  and  are the overall significance level and type II error rate, 
respectively.
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  Similar to  , the assurance probability of the second similarity 
criterion (ii) denoted as  can be represented as below.
   ≥   



∞

  
 
  

             (6)
where
 
  
   
  
        
   
In conclusion, the method suggested by Ko et al. (2010) determines , 
the proportion of patients out of  in the first region, to ensure that 
the assurance probabilities for similarity criteria (i) and (ii) under the 
alternative hypothesis for the first purpose of MRCTs (From here on 
referred to as the primary alternative hypothesis)   ∆   are 
maintained at a desired level, say, 80%. Here, a higher assurance 
probability is better.  
3.2. Limitations of Ko et al.'s method
  In MRCTs, along with the first purpose of validating the treatment 
effect of developing drug in all participating regions, there is the 
second purpose to demonstrate that the effects of the developing drug 
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is not sensitive to the region. For the second purpose, consistency 
assessment can be conducted to demonstrate that the result is not 
sensitive to each region after hypothesis testing for the overall trial 
results.
  The assurance probabilities method suggested by Ko et al. (2010) is 
inappropriate for evaluating the assurance probabilities under the 
primary alternative hypothesis which is the hypothesis for the first 
purpose of MRCTs. According to the method by Kang et al. (2016), as 
suggested in this thesis, the assurance probabilities should not be 
assessed based on the primary alternative hypothesis, but on the 
secondary alternative hypothesis for the second purpose of MRCTs 
with focus on assessing the similarity of treatment effects across 
regions. The reasons can be found in the concept of the assurance 
probabilities suggested by Ko et al. (2010). The purpose of the 
assurance probabilities is to assess consistency of treatment effects 
between the region of interest and all participating regions under the 
condition that the primary hypothesis is accepted. Specifically, the 
purpose is to confirm the assumption that all regions show an similar 
treatment effect. Therefore, such a purpose can be interpreted to be a 
process to test the following secondary hypothesis.
∙ refers to the secondary null hypothesis that claims the similarity 
in treatment effects between the region of interest and all 
participating regions. 
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∙ refers to the secondary alternative hypothesis that claims there 
is no similarity in treatment effects between the region of interest 
and all participating regions.   
There are many ways to express the secondary hypothesis as a 
statistical hypothesis, but the generally used method is as written 
below. 
  There is no difference in new treatment effects between regions.

  There is a difference in new treatment effects between regions.  
In reference to the aforementioned secondary hypothesis for the 
second purpose of MRCTs, the assurance probabilities suggested by Ko 
et al. (2010) can be considered a probability that satisfies the 
similarity criteria under . In the method suggested by Kang et al. 
(2016), as introduced in this thesis, the probability of not satisfying 
the similarity criteria under the secondary null hypothesis is referred 
to as a regional type I error rate. The assurance probabilities 
suggested by Ko et al. (2010), under the assumption that the treatment 
effects in the region of interest and other regions excluding the region 
of interest are identical, achieve exactly the same value as subtracting 
the regional type I error rate from 1. This is obtained through the 
method by Kang et al. (2016), which will be discussed in the next 
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section. 
  The regional type I error rate represents the probability of error to 
arrive at the incorrect conclusion of significant regional difference, 
despite the lack of difference in treatment effects between regions. On 
the other hand, the regional type II error represents the probability of 
error to arrive at the incorrect conclusion of no significance in 
regional difference, although there is a significant difference in 
treatment effects between regions. Therefore, when the hypothesis is 
tested about the second purpose of MRCTs , the regional type II error 
is more serious than the regional type I error.
  To calculate the number of clinical trial subjects required for the 
region of interest using a method to control regional type I error, as 
in the method using the assurance probabilities by Ko et al. (2010), 
the secondary null hypothesis would be assumed to be true. In this 
case, since it is assumed that there is no difference in new treatment 
effects between regions, a contradiction arises, which is that there is 
no need to assign sufficient number of patients for the region of 
interest. Therefore, it is more important to control regional type II 
error than regional type I error to calculate the number of required 
clinical trial subjects for the region of interest under the secondary 
hypothesis and thus the method proposed by Ko et al. (2010) would 
not be appropriate. 
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Chapter 4. Regional error rate
4.1. Proposed method using the assurance probability 
  In order to introduce the method suggested by Kang et al. (2016), 
the assurance probability  based on the second similarity 
criterion (ii)  ≥  proposed in the Japanese MHLW will be used. 
The main concepts of the suggested method are as follows.
(ⅰ)  ≥  is assessed considering that it is a statistical hypothesis 
testing procedure to test the secondary hypothesis stated in 
section 3.2, where  and  are regarded as a test statistic and 
a critical value, respectively. Under the assumption that the 
primary alternative hypothesis is accepted,  is greater than 0 
and thus   ≥  and  ≥  are the same.  
(ⅱ) Considering that the type II error is more serious than the type I 
error under the secondary hypothesis, the type II error rate with 
the secondary hypothesis is used to determine the associated 
parameters and the sample size in the region of interest. 
  In order to assess whether  ≥  is satisfied through the 
statistical hypothesis testing procedure, there is a need to formulate 
the secondary hypothesis in section 3.2 into a statistical hypothesis. 
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Although there are many ways to express the secondary hypothesis in 
the forms of statistical hypothesis, in this thesis, the most commonly 
used hypotheses equations (7) and (8) will be applied. Let ∆ and ∆
be the treatment effects in the region of interest and all regions 
participating in the clinical trial, respectively,
∆      and  ∆    
with  and  as the population means of the primary endpoint for 
the new treatment and placebo groups in the first region. If  is a 
natural estimator of ∆∆, the secondary hypothesis can be expressed 
as follows,   
                      ∆
∆
≥    vs     ∆
∆
                (7)
Here, subscript “s" was used to indicate that the hypothesis refers to 
the secondary hypothesis. The hypothesis in (7) is called the 
secondary hypothesis, because the equation (1) refers to the primary 
hypothesis for the first purpose of MRCTs. Since the rejection region 
   according to the similarity criterion (ii) is one-sided, the 
hypothesis in (7) should also be a one-sided. The secondary 
alternative hypothesis in (7) shows that the new treatment effect in the 
first region is less than that of all regions, which is a major concern 
from the perspective of regulatory agencies. In other words, it can be 
concluded that treatment effects are similar between regions only 
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when treatment effects in the region of interest is the same or greater 
compared to that of all regions. 
  The secondary hypothesis can applied to the similarity criterion (i)  
 ≥  to be expressed as shown below.
                     ∆
∆
≥    vs     ∆
∆
                (8)
where ∆ is the treatment effect in all regions excluding the first 
region. The fact that ∆ can be expressed in terms of ∆, ∆ and 
is important in explaining the relationship between equations (7) and 
(8) in the secondary hypothesis. Here,  represents the ratio of total 
number of patients in the first region to the total number of patients 
in all participating regions ∆ can be expressed as shown below. 
                         ∆  ∆    ∆                      (9)
The relationship of equation (9) is explained in Appendix A. Assuming 
the value of  is approximately known and the primary alternative 
hypothesis is accepted, the secondary null hypothesis on the similarity 
criterion (i)  ∆∆≥  becomes  ∆∆≥ . Using equation (9) 
results in   ∆ ≥ ∆  ∆ and rearranging the right clause 
gives    ∆ ≥ ∆, deriving the final equation 
  ∆ ≥∆, which is identical to the equation of the secondary null 
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hypothesis (8) of the second similarity criterion (ii). 
  The type I error related to the secondary hypothesis can be 
interpreted as an error resulting in the incorrect conclusion that 
there is a difference in treatment effects, despite the similar treatment 
effects of the new treatment in all participating regions and the first 
region of the clinical trial. On the other hand, the type II error 
related to the secondary hypothesis is an error resulting in the 
incorrect conclusion that there is no difference in treatment effects, 
despite the difference in treatment effects of new treatment in all 
participating regions and the first region of the clinical trial. From the 
perspective of regulatory authorities, an incorrect conclusion that 
claims the similarity when there is a difference, compared to the 
incorrect conclusion that claims a difference in treatment effects 
despite the similarity, is more serious. This is due to the fact that the 
type I error does not result in drug approval and therefore, although 
it may be conservative to  developers, there is no serious risk for 
regulatory agencies. In contrast, the type II error would result in drug 
approval, leading to significant risk for the regulatory agencies. 
Therefore, decisions should be made with a greater focus on the type 
II error rather than on the type I error. From here on, the type I 
error and the type II error related to the secondary hypothesis will be 
referred to as the regional type I error and the regional type II error. 
  The second similarity criterion  ≥  results in the equations 
below for the regional type I error rate (10) and the regional type II 
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error rate (11).
                                         (10)
                         ≥                (11)
The regional type II error rate can be understood as a similar concept 
to the assurance probability, as it is actually assessed based on the 
secondary alternative hypothesis. As mentioned in chapter 3, the 
higher assurance probability suggested by Ko et al. (2010) is better but 
for the regional type II error rate, a lower rate is preferred. 
  In general, the critical value of a statistical hypothesis testing 
procedure should be determined under the null hypothesis in order to 
control the type I error rate under the significance level, as the type I 
error is more serous than the type II error. However, as mentioned, 
in the statistical hypothesis testing in equations (7) and (8) on the 
secondary hypothesis of MRCTs, regulatory agencies consider the 
regional type II error to be more serious than the regional type I 
error. Therefore, the regional type II error rate should be used to 
determine the sample size for clinical trials in the first region as well 
as associated parameters including critical value  and the proportion 
of patients out of 2 in the region of interest .
  The regional type I error rate and the regional type II error rate for 
the first similarity criterion (i)  ≥  (    ) using the concept 
in equations (10) and (11) are shown below. From here, the regional 
- 24 -
type II error rate and the regional type I rate for the first similarity 
criterion (i) are  and , respectively.
             ≥       ∆∆              (12)
             

∞
∞
  

  




∞


  

  

  


   
                   ∆∆ ≥             (13)
              

∞
∞
  

  




∞
    

  


where
  



,    




∆
 
∆
 ,     ,  
   ,    




∆
 
∆
 ,
     
  
,     
  
The regional type II error rate and the regional type I error rate for 
the second similarity criterion (ii)  ≥  (    ) are shown 
below. As with the similarity criterion (i), the regional type II error 
rate and the regional type I rate for the second similarity criterion (ii) 
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are  and , respectively.   
               ≥       ∆∆             (14)
  

∞
∞
  

  




∞


  

  

  


                      ∆∆≥             (15)


∞
∞
  

  




∞
    

  


where 
  

,    




∆





∆
,     ,  
   ,    




∆
 
∆
 ,  
     
  
,     
  
The mathematical derivations of the regional type II error standardized 
by the effect size of the first region (∆) and other regions (∆)  
are provided in Appendix B. In the case of the regional type I error 
rate, the mathematical derivations are similar to those of the regional 
type II error rate and therefore is not shown here. Equations (12) and 
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(14) show that the regional type II error rate is dependent on , , , 
, ∆ and ∆. The total sample size  per group calculated 
during the planning of MRCTs is determined by the overall 
significance level , a given power and the overall effect size. 
Therefore, in calculating the regional type II error rate, , ,  and 
∆ should be considered as fixed constants and only , , ∆ and 
∆ should be recognized as parameters to be considered in the 
calculation.  
  In order to assess the similarity in the treatment effects in the first 
region according to similarity criteria (i) or (ii), the selection of critical 
value is extremely important. If regional type II error rates  or 
were to be used to set the critical value , then the values for , , 
∆ and ∆ should be determined beforehand. As mentioned, 
can be considered as a fixed constant determined during the planning 
of MRCTs and thus there is a need to provide evidence to determine  
, ∆ and ∆. In order to use regional type II error rates to 
calculate critical value , there are two situations to set . The first 
situation is that the value can be determined before the initiation of 
an MRCT based on the conditions of clinical trial recruitment in the 
region of interest or the cost of the trial rather than on statistical 
grounds. The second situation is that the value can be determined for 
the sake of competitive registration of patients between regions to 
increase the speed of registration in the clinical trial. The second 
situation, unlike the first situation, provides the proportion of patients 
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from the first region as soon as the planned number of subjects is 
registered and follow-ups of patient are complete in the MRCT. Since 
both cases can be used to set , if effect sizes (∆ and ∆) are 
assumed based on clinical or regulatory evidence and the regional 
type II error rate is specified in advance for example 10% or 20% then 
the critical value  that assesses the similarity while satisfying such a 
regional type II error rate can be calculated. In general, when 
designing an MRCT, the overall effect size ∆ is set based on results 
from the literature, previous studies or regulations. Similarly, ∆
and ∆ can be set using the literature or previous studies, as well 
as on an empirical or regulatory basis. In this thesis, calculated 
results of the  values that satisfy the pre-specified regional type II 
error rate and its examples will be discussed in section 5.2 and 
section 6.1, respectively.
  If regulatory agencies determine , ∆ and ∆ on an empirical 
or regulatory basis, regional type II error rates will be functions only 
dependent on . Therefore,  values that satisfy the pre-specified  
regional type II error rate, for example at 20%, can be determined. In 
other words, under the condition given by , ∆ and ∆, if the 
proportion of the number of patients in the first region to the number 
of patients in all participating region in the MRCT is , the regulatory 
authority in the first region will use the determined regional type II 
error rate to discover the difference between ∆ and ∆. 
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4.2. Distribution of the effect size through literature reviews
  As mentioned in section 4.1, the regional type II error rate depends 
on , , ∆ and ∆. The critical value  for assessing the 
similarity and the proportion of patients to be assigned in the first 
region that satisfy the pre-specified regional type II error rate change 
with the effect sizes of the first region and other regions excluding 
the region of interest. This section investigates the results of actual 
clinical trials through literature review in order to determine the 
assumed range for effect sizes ∆ and ∆. This was done to 
allow calculations for the proportion of patients out of  in the first 
region  which satisfies the given regional type II error rate and 
critical value  to assess the similarity.
  The literature review was conducted using the results of the FDA 
statistical review on new molecular entity and therapeutic biological 
products for market release approval by the US FDA from 2011 to 
2014. To apply the investigated clinical trial results to this thesis, 
phase III clinical trials with placebo group and a continuous variable 
as the primary endpoint were selected. The following procedure was 
used to investigate FDA approved drugs from 2011 to 2014.
(ⅰ) First step of investigation
An annual list of drugs was generated from the website below for 
the period between 2011 and 2014.
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Research site:
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ 
DrugInnovation/default.htm
(ⅱ) Second step of investigation
For each of the listed drugs, the website stated below was used to 
search for active ingredients and the results were organized using 
the FDA statistical Review.
Search site:
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ 
  The effect sizes of new drugs that were investigated from 2011 to 
2014 are listed in Table A1 of Appendix C. Table 1 summarizes the 
effect sizes from Table A1 to suggest basic statistics.
Table 1. Summary of the effect size of approved drugs from 2011 to 
2014
Mean SD Median 25% percentile
75% 
percentile MIN MAX
0.68 0.39 0.58 0.41 0.96 0.03 1.7
  Fukunaga et al. (2014) investigated effect sizes and research designs 
of Phase II and III clinical trials on approved drugs for depression, 
schizophrenia, asthma, high blood pressure and diabetes in Japan 
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from 1970 to 2011. The range of effect sizes investigated by Fukunaga 
et al. (2014) was from -0.64 to 1.94 and the average was 0.19. Since 
not only did this result include placebo controlled comparison clinical 
trials, active comparator controlled treatment clinical trials and failed 
clinical trial results but also a relatively limited number of diseases 
was investigated, the results were broader than that of this thesis. 
However, the box-whisker plot of effect sizes of each disease 
separated by an comparator controlled and placebo controlled groups 
confirms the appropriateness of the effect size range suggested in this 
thesis. 
  In this thesis, the assumed range of ∆ and ∆ for calculating 
 and  that satisfy the pre-specified regional type II error rate is set 
from 0.4 to 0.9 which corresponds roughly between the 20% and 75% 
percentiles in Table 1.
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Chapter 5. Results
5.1.  and  according to the effect size
  
  In this section, regional type II error rates  and  according to 
the effect sizes of the region of interest and other regions excluding 
the region of interest, the proportion of patients assigned to the 
region of interest and the critical value to assess the similarity were 
calculated and the changes were confirmed. In particular, in cases 
where  and  are fixed (for example, in cases where regulatory 
agencies use empirical or regulatory basis), the changes in regional 
type II error rates with changes in the effect sizes in the region of 
interest and other regions were studied. Calculations for the regional 
type II error rate were conducted based on the conditions described 
below.
1) 
2) ≤≤, 100 unit change
3) Effect size : ≤∆≤, 0.1 unit change
3) Effect size : ≤∆≤ unit change
4) ≤≤, 0.1 unit change
5) ≤ ≤, 0.1 unit change
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  Calculated regional type II error rates according to the conditions 
above are not all provided in a table but the representative regional 
type II error rates  and  for =500, =0.5, 0.7, 0.9 and effect 
size in region of interest ∆=0.1 are shown in Table 2. Regional type 
II error rates are written as 0.00 in the table if they were smaller than 
0 after rounding at the 3rd decimal place.
  Taking the first row of Table 2 as an example, the values are 
regional type II error rates  and  according to  when the 
significance level is 0.025,  is 0.5, ∆ is 0.1 and ∆ is 0.2. If 
is 0.1,  and  corresponding to similarity criteria (i) and (ii) are 
0.52 and 0.53, respectively.
  Figure 1 shows the relationship between  or  and the 
proportion of patient out of  in the first region  for  values from 
some of the results in Table 1. This includes combinations of ∆
and ∆ to be (0.1, 0.2), (0.1, 0.3), and (0.1, 0.4). 
  It can be confirmed through Table 2 and figure 1 that if , ∆, 
∆ and  are the same, respectively,  associated with the 
similarity criterion (i) is smaller than  associated with the similarity 
criterion (ii). When the proportion of patients in the region of interest 
 is small, there is little difference between  and , but as the 
value of  approaches 1, the difference between  and 
increases. Furthermore, when  and  are the same, respectively, as 
the difference between ∆ and ∆ increases, the difference 
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between  and  decreases. And when , ∆ and ∆ are the 
same, respectively, as  increases  and  decrease.
  When ∆  and ∆ ,  and  cannot be lower than 
20%, regardless of  or similarity criteria. However as the difference 
between ∆ and ∆ and  value increases,  and  show a 
tendency to be lower than 20% but increases with  increase. 
Concerning the similarity criterion (i), as the difference between ∆
and ∆ increases and  and  increases,  shows decreases and 
then increases after a certain point. However, the range is small. On 
the other hand, for the similarity criterion (ii), if the difference 
between ∆ and ∆ are not small and the  value is small, as 
increases  also increases greatly. For example, if  is 0.5 and ∆
and ∆ are 0.1 and 0.2, respectively, as  approaches 1, 
increases from 0.5 to over 0.6 and then decreases, but  increases 
with  increase. In the same condition, if  is 0.9,  decreases until 
 is 0.5 and increases as  approaches 1. However, the difference 
between the decreasing magnitude before   and the increasing 
magnitude after   are not significantly large and similar. On the 
other hand,  showed a tendency to decrease until  is around 0.5 
and then considerably increased as  approached 1.
- 34 -
Table 2. The regional type II error rate when 
 
∆

∆
 :  　  : 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 　 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0.5 0.1 0.2 0.52 0.53 0.54 0.56 0.57 0.59 0.60 0.61 0.60 　 0.53 0.56 0.61 0.67 0.74 0.82 0.90 0.97 1.00 
　 　 0.3 0.40 0.37 0.35 0.33 0.33 0.34 0.35 0.38 0.42 　 0.42 0.41 0.43 0.47 0.54 0.64 0.77 0.91 1.00 
　 　 0.4 0.31 0.25 0.21 0.18 0.16 0.16 0.16 0.19 0.26 　 0.33 0.30 0.29 0.32 0.37 0.46 0.61 0.82 0.99 
　 　 0.5 0.23 0.15 0.11 0.08 0.07 0.06 0.06 0.08 0.14 　 0.25 0.20 0.19 0.20 0.24 0.31 0.45 0.69 0.97 
　 　 0.6 0.16 0.09 0.05 0.03 0.02 0.02 0.02 0.03 0.06 　 0.18 0.13 0.11 0.12 0.14 0.21 0.32 0.56 0.93 
　 　 0.7 0.11 0.04 0.02 0.01 0.01 0.00 0.00 0.01 0.02 　 0.13 0.07 0.06 0.06 0.08 0.12 0.22 0.44 0.88 
　 　 0.8 0.07 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.01 　 0.08 0.04 0.03 0.03 0.04 0.07 0.15 0.34 0.81 
　 　 0.9 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.05 0.02 0.01 0.01 0.02 0.03 0.09 0.26 0.73 
　 　 1.0 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.03 0.01 0.00 0.00 0.01 0.02 0.05 0.19 0.64 
　 　 1.1 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.02 0.00 0.00 0.00 0.00 0.01 0.03 0.13 0.56 
　 　 1.2 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.09 0.49 
0.7 0.1 0.2 0.43 0.41 0.40 0.39 0.39 0.40 0.41 0.42 0.44 　 0.44 0.44 0.45 0.48 0.53 0.60 0.70 0.83 0.96 
　 　 0.3 0.30 0.23 0.20 0.17 0.17 0.17 0.18 0.21 0.27 　 0.31 0.26 0.25 0.26 0.29 0.36 0.47 0.66 0.91 
　 　 0.4 0.19 0.11 0.08 0.06 0.05 0.05 0.06 0.08 0.14 　 0.20 0.14 0.12 0.11 0.13 0.17 0.26 0.46 0.83 
　 　 0.5 0.11 0.05 0.02 0.02 0.01 0.01 0.01 0.02 0.06 　 0.12 0.06 0.05 0.04 0.05 0.07 0.13 0.28 0.72 
　 　 0.6 0.06 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.02 　 0.07 0.03 0.01 0.01 0.01 0.02 0.05 0.16 0.58 
　 　 0.7 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 　 0.03 0.01 0.00 0.00 0.00 0.01 0.02 0.08 0.44 
　 　 0.8 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.32 
　 　 0.9 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.22 
0.9 0.1 0.2 0.35 0.31 0.28 0.27 0.26 0.27 0.28 0.30 0.35 　 0.36 0.32 0.30 0.30 0.31 0.34 0.38 0.47 0.63 
　 　 0.3 0.21 0.14 0.10 0.09 0.08 0.08 0.10 0.13 0.20 　 0.21 0.15 0.12 0.11 0.11 0.12 0.16 0.25 0.45 
　 　 0.4 0.11 0.05 0.03 0.02 0.02 0.02 0.02 0.04 0.09 　 0.11 0.05 0.03 0.03 0.02 0.03 0.05 0.10 0.28 
　 　 0.5 0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.04 　 0.05 0.01 0.01 0.00 0.00 0.01 0.01 0.03 0.15 
　 　 0.6 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 　 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.07 
　 　 0.7 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 　 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03 
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        
∆∆      ∆ ∆     ∆ ∆ 
Figure 1. Graph of the regional type II error rate vs  when 
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5.2. Critical value  selection according to the effect size
  
  Selection of critical value  to assess the similarity is an important 
standard that determines the similarity between treatment effects in 
the region of interest and all regions. According to Ko et. al. (2010), 
selection of  needs to consider the ethnic factors between the region 
of interest and other regions, and it can be decided by the regulatory 
authorities in the region. The Japanese MHLW guideline recommends 
that the  value should be over 0.5 in the similarity criterion (ii) 
 ≥, but does not discuss the standard for the selection from a 
statistical perspective. 
  In this section, the changes in critical value  according to the 
regional type II error rate will be investigated in order to discuss a 
method to select a  value that satisfies the pre-specified regional 
type II error rate.
5.2.1. Conditions for  and  calculation to select 
  The critical value  for the similarity criteria should be determined 
during the planning of the clinical trial design. In order to select a 
value during clinical trial planning, the effect sizes of the region of 
interest and other regions excluding the region of interest should be 
assumed. In this section, in order to select a  value in a condition 
similar to that of a real clinical trial environment, effect sizes based 
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on literature review will be used to calculate regional type II error 
rates  and . 
  Effect sizes based on literature review of results of US FDA review 
on approved drugs from 2011 to 2014, as mentioned in section 4.2, 
were set to change in units of 0.05, within the range of 0.5-0.9. The 
total sample size per group  was assumed to be 100, 300, 500, 700, 
1,000, and 1,500, and the critical value  for similarity criteria was set 
in units of 0.001, within the range 0.5-0.99. 
  The proportion of patients out of 2 in the region of interest  was 
determined using the presented results from a Pharmaceutical and 
Medical Devices Agency (PMDA) biostatistics summer workshop in 2012  
(Ando, 2012). From the literature review of Ando (2012), MRCT results 
of Japanese PMDA approved drugs from Feb 2006 to June 2012 were 
used to investigate the assigned ratio in the Japan and Asia region. 
The range of the ratio was set to 0.05-0.5, which included the 25th 
percentile to 75th percentile from the investigated results. And Regional 
type II error rate calculation was conducted within this range by 
changing by 0.05.
[Summary of  and calculation conditions to select  value]
(1) 
(2) Effect size : ≤∆≤, ≤∆≤ , 0.05 unit change
(3) 100, 300, 500, 700, 1,000, 1,500
(4) ≤≤, 0.001 unit change
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(5) ≤ ≤, 0.05 unit change
5.2.2. Selection of a  value that satisfies the pre-specified 
 and 
  To determine a  value that satisfies the pre-specified regional type 
II error rate,  values were calculated for when regional type II error 
rates are 10%, 15%, 20%, 25%, 30% and 35% for each similarity 
criterion according to the changes in , , ∆ and ∆.
  The calculated results from the conditions above are not all listed in 
this thesis due to space limitations. However, the results for when 
is 500 and the  values that satisfy the pre-determined regional type 
II error rates (10%, 20%, and 30%) according to the combination of 
effect sizes (∆, ∆）are listed by  values in Table A2 of 
Appendix D. In Table A2, the empty cells refer to  values larger than 
1 after rounding at the 3rd decimal place. For these cells,  can be 
considered to be 1 because the range of  values is between 0 and 1. 
In addition, the combinations of ∆ and ∆ that are not listed in 
Table A2 among the range of effect size in section 5.2.1, are the 
cases where the  value that satisfies the regional type II error rate is 
not between 0 and 1. In other words, if the  value that satisfies the 
regional type II error rate is greater than 1, it is not listed in the 
table and those empty cells can be assumed to be 1.
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  Table 3 is an excerpt of Table A2 only when ∆ is 0.4. Table 3 
shows that when  or  is the same, and , ∆, ∆ and 
are the same, respectively, the critical value  for the similarity 
criterion (ii) is greater than the critical value  for the similarity 
criterion (i). When all other parameter conditions are the same, 
respectively, the similarity criterion (ii) can be seen as more 
conservative in assessing the similarity of effect size in the region of 
interest than the similarity criterion (i). In other words, if all 
parameters are the same, respectively, even if there is no actual 
similarity, there is a higher probability of the similarity criterion (i) to 
assess the case to be similar than the similarity criterion (ii). 
Furthermore, if  and  are the same, respectively, the  value that 
satisfies the pre-determined  or  decreases as the difference 
between the effect sizes of the first region ∆ and other regions 
∆ increases. This phenomenon indicates that when the effect size 
in the region of interest is considerably smaller than that of other 
regions, the critical value  of the similarity is further reduced in 
assessing the similarity. For additional explanation, suppose that the 
effect size in the region of interest is predicted to be much smaller 
than that of other regions. In spite of this difference of the effect 
size, if the MRCT is conducted because there are no clinically ethnic 
differences in the treatment effect of the new treatment, critical value 
 needs to be reduced in order to increase the possibility of 
confirming the similarity.
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  The above-mentioned properties can also be seen in Figure 2. The 
figure shows the  values that satisfy  and  at 20% in relation 
to the changes of  when  is 500 and the combination of the effect 
sizes in the region of interest and other regions (∆∆) are (0.4, 
0.6), (0.4, 0.7), (0.4, 0.8) and (0.4, 0.9). As shown in Figure 2, when , 
, ∆ and  (or ) are the same, respectively, as ∆
increases the  value decreases. Accordingly, the  value for the 
similarity criterion (i) is smaller than that of the similarity criterion 
(ii). Furthermore, the  value that satisfies the pre-determined 
and  decreases as  increases and increases after a certain , 
regardless of similarity criteria (i) or (ii). The regional type II error 
rate also decreases as  increases. This can be easy to verify that the 
regional type II error rates are decreasing functions of , since 
functions (12) and (13) for the regional type II error rate include 
only in  and , respectively.
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Table 3. Selection of  that satisfies the pre-determined regional type II error rate when 

or


∆

∆
 : Similarity criteria (i) 　  : Similarity criteria (ii)
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
0.10 0.40 0.60 　 　 　 1.00 0.97 0.95 0.94 0.93 0.92 0.92 　 　 　 　 1.00 0.98 0.97 0.96 0.96 0.96 0.96 
　 　 0.65 　 　 0.96 0.92 0.89 0.87 0.86 0.85 0.85 0.84 　 　 　 0.96 0.93 0.92 0.91 0.90 0.91 0.91 0.91 
　 　 0.70 　 0.95 0.88 0.85 0.82 0.81 0.79 0.79 0.78 0.77 　 　 0.95 0.90 0.87 0.86 0.86 0.86 0.86 0.87 0.87 
　 　 0.75 　 0.88 0.82 0.79 0.77 0.75 0.74 0.73 0.72 0.72 　 　 0.89 0.85 0.82 0.81 0.81 0.81 0.82 0.83 0.84 
　 　 0.80 0.95 0.83 0.77 0.74 0.72 0.70 0.69 0.68 0.67 0.67 　 0.96 0.84 0.80 0.78 0.77 0.77 0.77 0.78 0.79 0.80 
　 　 0.85 0.90 0.78 0.72 0.69 0.67 0.66 0.65 0.64 0.63 0.63 　 0.90 0.79 0.75 0.74 0.73 0.73 0.74 0.75 0.76 0.77 
　 　 0.90 0.85 0.73 0.68 0.65 0.63 0.62 0.61 0.60 0.59 0.59 　 0.85 0.75 0.72 0.70 0.70 0.70 0.71 0.71 0.73 0.74 
0.20 0.40 0.55 　 　 0.99 0.96 0.94 0.93 0.92 0.92 0.91 0.91 　 　 　 0.99 0.97 0.96 0.95 0.95 0.95 0.95 0.95 
　 　 0.60 　 0.96 0.91 0.88 0.86 0.85 0.84 0.83 0.83 0.83 　 　 0.96 0.92 0.90 0.89 0.89 0.89 0.89 0.90 0.91 
　 　 0.65 0.98 0.88 0.84 0.81 0.79 0.78 0.77 0.77 0.76 0.76 　 0.98 0.89 0.86 0.84 0.84 0.84 0.84 0.85 0.85 0.86 
　 　 0.70 0.91 0.82 0.77 0.75 0.73 0.72 0.71 0.71 0.70 0.70 　 0.92 0.83 0.80 0.79 0.79 0.79 0.79 0.80 0.81 0.82 
　 　 0.75 0.85 0.76 0.72 0.70 0.68 0.67 0.66 0.66 0.65 0.65 　 0.86 0.78 0.75 0.74 0.74 0.75 0.75 0.76 0.78 0.79 
　 　 0.80 0.80 0.71 0.68 0.65 0.64 0.63 0.62 0.62 0.61 0.61 　 0.81 0.73 0.71 0.70 0.70 0.71 0.72 0.73 0.74 0.76 
　 　 0.85 0.75 0.67 0.64 0.61 0.60 0.59 0.58 0.58 0.57 0.57 　 0.76 0.69 0.67 0.67 0.67 0.67 0.68 0.70 0.71 0.73 
　 　 0.90 0.71 0.63 0.60 0.58 0.57 0.56 0.55 0.55 0.54 0.54 　 0.72 0.66 0.64 0.63 0.64 0.64 0.65 0.67 0.68 0.70 
0.30 0.40 0.50 　 　 0.98 0.96 0.95 0.94 0.93 0.93 0.93 0.93 　 　 　 0.98 0.97 0.96 0.96 0.96 0.96 0.96 0.96 
　 　 0.55 1.00 0.92 0.89 0.87 0.86 0.85 0.84 0.84 0.84 0.84 　 1.00 0.93 0.90 0.89 0.89 0.89 0.89 0.90 0.90 0.91 
　 　 0.60 0.91 0.84 0.81 0.80 0.79 0.78 0.77 0.77 0.77 0.76 　 0.92 0.86 0.84 0.83 0.83 0.83 0.84 0.85 0.86 0.87 
　 　 0.65 0.84 0.78 0.75 0.73 0.72 0.72 0.71 0.71 0.70 0.70 　 0.85 0.80 0.78 0.78 0.78 0.78 0.79 0.80 0.81 0.83 
　 　 0.70 0.78 0.72 0.70 0.68 0.67 0.66 0.66 0.66 0.65 0.65 　 0.79 0.74 0.73 0.73 0.73 0.74 0.75 0.76 0.77 0.79 
　 　 0.75 0.73 0.67 0.65 0.64 0.63 0.62 0.61 0.61 0.61 0.61 　 0.74 0.70 0.69 0.69 0.69 0.70 0.71 0.72 0.74 0.75 
　 　 0.80 0.68 0.63 0.61 0.60 0.59 0.58 0.57 0.57 0.57 0.57 　 0.69 0.66 0.65 0.65 0.65 0.66 0.68 0.69 0.71 0.72 
　 　 0.85 0.64 0.59 0.57 0.56 0.55 0.55 0.54 0.54 0.53 0.53 　 0.65 0.62 0.61 0.61 0.62 0.63 0.64 0.66 0.68 0.69 
　 　 0.90 0.61 0.56 0.54 0.53 0.52 0.51 0.51 0.51 0.50 0.50 　 0.62 0.59 0.58 0.58 0.59 0.60 0.62 0.63 0.65 0.67 
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 
Figure 2. Graph of  vs  when the regional type II error rate is 20%
5.3. Selection of  according to the effect size
  The sample size in the region of interest is investigated by selecting 
 that satisfies  for the similarity criterion (i) or  for the 
similarity criterion (ii) according to the critical value  to assess the 
similarity, the changes of the effect size in the region of interest ∆
and the changes of effect size in other regions ∆.
- 43 -
5.3.1. Conditions for  and  calculation to select 
  The proportion of patients out of  in the region of interest  was 
calculated according to the size of  and  for the similarity 
criteria by changing the ranges of effect size (∆ ∆),  and . 
Here, the range of effect sizes was limited to 0.4-0.9 and 0.1-0.5, 
respectively with unit change of 0.05 to present . The reason for 
dividing the effect size range into two was as follows: the effect size 
range of 0.4-0.9 was chosen using the FDA review results of approved 
drugs from 2011 to 2014 from section 4.2 and the range was between 
the 25th percentile and the 75th percentile of the investigation results. 
In general, if a significance level , power  and an expected 
treatment effect ∆ are given, then the equation to calculate the 
overall sample size for each group in the clinical trial is as shown in 
the widely known equation (2). In order to calculate the number of 
required clinical trial subjects, it is customary to assume power 
to be between 80%-90%. The expected treatment effect is estimated 
based on previous clinical trials or literature review to compute the 
sample size. Using equation (2) for the required number of clinical 
trial subjects, if the significance level ,  and power  are 
pre-determined, then the expected effect size ∆  can be 
calculated as shown below. 
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                          

  



                     (17)
As mentioned, since power in clinical trials is conventionally set 
between 80%–90%, when the number of subjects for each group in the 
trial  is set to 100, 300, 500, 700, 1,000, and 1,500 with the 
significance level  and the given power range, the expected 
effect size commonly used in the sample size calculation is as shown 
in Table 4. The table shows that when  is 100 and power is between 
80% and 90%, the effect size is between 0.4 and 0.46; when  is 500, 
the effect size is between 0.18 and 0.21; and when  is 1,500, the 
effect size is between 0.1 and 0.12. This shows that as  increases, 
the effect size decreases. If Table 4 was to be used to design clinical 
trial with power within 80%-90% and  below 1,500, the configurable 
effect size is predicted to be between 0.1 and 0.5. For this reason, to 
calculate the proportion of required subjects for clinical trial in the 
region of interest in real clinical trial conditions, the range of 0.1-0.5 
was additionally included to be used in the regional type II error 
calculation for  selection.
  As a calculation condition for selecting , the overall sample size 
per group  was set to 100, 300, 500, 700, 1,000 and 1,500 and 
critical value  for the similarity assessment was set between 0.5 and 
0.9 with 0.1 unit change. Furthermore,  was changed within the 
range of 0-0.9, with 0.0002 unit change to calculate  and  for 
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selecting a  that satisfies the pre-specified regional type II error 
rate. Here, the significance level  was 0.025.
Table 4. Expected effect size according to  and 
      ∆
0.9 100 0.025 1.96 1.28 0.46 
0.9 300 0.025 1.96 1.28 0.26 
0.9 500 0.025 1.96 1.28 0.21 
0.9 700 0.025 1.96 1.28 0.17 
0.9 1,000 0.025 1.96 1.28 0.14 
0.9 1,500 0.025 1.96 1.28 0.12 
0.85 100 0.025 1.96 1.04 0.42 
0.85 300 0.025 1.96 1.04 0.24 
0.85 500 0.025 1.96 1.04 0.19 
0.85 700 0.025 1.96 1.04 0.16 
0.85 1,000 0.025 1.96 1.04 0.13 
0.85 1,500 0.025 1.96 1.04 0.11 
0.8 100 0.025 1.96 0.84 0.40 
0.8 300 0.025 1.96 0.84 0.23 
0.8 500 0.025 1.96 0.84 0.18 
0.8 700 0.025 1.96 0.84 0.15 
0.8 1,000 0.025 1.96 0.84 0.13 
0.8 1,500 0.025 1.96 0.84 0.10 
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[Summary of  and  calculation conditions for  value selection]
(1) 
(2) Effect size 
   · Literature review: ≤∆≤, ≤∆≤
   · Literature review: 0.05 unit change
   · Actual clinical trial condition : ≤∆≤, ≤∆≤
           0.05 unit change
(3) 100, 300, 500, 700, 1,000, 1,500
(4) ≤≤, 0.1 unit change
(5) ≤ ≤, 0.0002 unit change
5.3.2.  calculation for the sample size in the region of 
interest
   values that satisfy  and  according to the effect sizes and 
the changes in the  value were calculated and the results are listed 
in Table A3 of Appendix E, when  values are 0.8 and 0.9, regional 
type II rates are 10%, 15%, 20%, 25%, 30% and 35% and effect sizes of 
the region of interest are 0.2 and 0.4. Table 5 is the table when  is 
0.9 and  and  satisfy 0.15 and 0.2 in Table A3 of Appendix E. 
The empty cells in the table refer to cases without  that satisfies the 
pre-specified regional type II error rate for the given condition of , 
, ∆ and ∆ and thus the regional type II error rate is not 
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below 0.15 or 0.2 within the  range of 0-1. For example, when 
 , ∆ , ∆  and ,  or  is never lower 
than 0.2 within the range of . In addition,  values, which is 
calculated in the ranges of ∆ and ∆ not shown in the table, 
are not included in the table because  or  is never lower than 
0.1 or 0.2 with the  range of 0-1.
  As an example of the interpretation of the values in the table, when 
the overall sample size per group is 1,000, ∆ , ∆ , 
  and the similarity criterion (i) is used to assess the similarity, 
 value which satisfies   is 0.2598. Therefore, the sample size 
for the region of interest is 260 per group, which means that the total 
number of patients for the region of interest in the MRCT is 520. 
When the similarity criterion (ii) is used to assess the similarity, 
value which satisfies   is 0.0792 and therefore the sample size 
per group for the region of interest is 80 making the total number of 
patient 160.
  When , , ∆ and ∆ are given,  does not monotonically 
increase or decrease with regional type II error rates , . As a 
result of this relationship, there can be two  values between 0 and 1 
for a pre-determined regional type II error rate, as can be seen in the 
 graph in relation to  or . Figure 3 is a scatter plot of 
and , and  and  for when ,  , ∆  and 
∆ . The plot shows that as  changes, there is no monotone 
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increase or decrease in  or . And it can be observed that there 
are no or more than one  value satisfying the pre-determined 
and . Furthermore, when other parameters (effect size, ) are 
fixed, the regional type II error rate does not go below a certain value 
as  decreases. This phenomenon occurs when there are cases with 
smaller difference between ∆ and ∆ and smaller  value 
assuming other parameters are fixed, and is also shown in Figure A1 
and A2 in Appendix F.
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Table 5.  to calculate the sample size in the region of interest when  
 or  ∆ ∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
0.15 0.2 0.35 　 　 　 0.3000 0.1846 0.1150 　 　 　 　 　 0.2228 0.1252 
　 　 0.40 　 0.4486 0.1922 0.1290 0.0868 0.0564 　 　 　 0.2242 0.1396 0.0910 0.0580 
　 　 0.45 　 0.1960 0.1078 0.0748 0.0512 0.0338 　 　 0.2240 0.1138 0.0774 0.0524 0.0342 
　 　 0.50 　 0.1224 0.0700 0.0492 0.0340 0.0224 　 　 0.1296 0.0722 0.0502 0.0344 0.0226 
　 0.4 0.55   　 　 　 　 0.3126  0.1792  　 　 　 　 　 　 　
　 　 0.60 　 　 0.2750 0.1764 0.1164 0.0748 　 　 　 　 0.2392 0.1330 0.0804 
　 　 0.65 　 0.2572 0.1358 0.0934 0.0636 0.0416 　 　 　 0.1548 0.1006 0.0668 0.0428 
　 　 0.70 　 0.1482 0.0838 0.0586 0.0404 0.0266 　 　 0.1682 0.0886 0.0608 0.0414 0.0270 
　 　 0.75 0.4704 0.0990 0.0572 0.0404 0.0280 0.0186 　 　 0.1054 0.0592 0.0412 0.0284 0.0188 
　 　 0.80 0.2582 0.0714 0.0418 0.0296 0.0206 0.0136 　 　 0.0740 0.0426 0.0300 0.0208 0.0138 
　 　 0.85 0.1828 0.0540 0.0318 0.0226 0.0158 0.0106 　 0.2076 0.0554 0.0324 0.0228 0.0158 0.0106 
　 　 0.90 0.1388 0.0424 0.0252 0.0178 0.0124 0.0084 　 0.1496 0.0432 0.0254 0.0180 0.0126 0.0084 
0.2 0.2 0.30 　 　 　 　 　 0.2292 　 　 　 　 　 　 　
　 　 0.35 　 　 0.2656 0.1712 0.1134 0.0728 　 　 　 　 0.2014 0.1232 0.0764 
　 　 0.40 　 0.2170 0.1176 0.0812 0.0556 0.0366 　 　 0.2666 0.1262 0.0850 0.0572 0.0372 
　 　 0.45 　 0.1196 0.0686 0.0482 0.0334 0.0220 　 　 0.1272 0.0708 0.0492 0.0338 0.0222 
　 　 0.50 0.3050 0.0774 0.0452 0.0320 0.0222 0.0148 　 　 0.0800 0.0460 0.0324 0.0224 0.0148 
　 0.4 0.55 　 　 　 0.2840 0.1766 0.1104 　 　 　 　 　 　 0.1322 
　 　 0.60 　 0.3182 0.1600 0.1088 0.0738 0.0482 　 　 　 0.2026 0.1226 0.0792 0.0502 
　 　 0.65 　 0.1514 0.0854 0.0596 0.0412 0.0272 　 　 0.1772 0.0914 0.0624 0.0424 0.0276 
　 　 0.70 0.3932 0.0928 0.0538 0.0380 0.0264 0.0174 　 　 0.0988 0.0556 0.0388 0.0268 0.0176 
　 　 0.75 0.2210 0.0632 0.0372 0.0264 0.0184 0.0122 　 0.2840 0.0654 0.0378 0.0266 0.0184 0.0122 
　 　 0.80 0.1520 0.0460 0.0272 0.0194 0.0136 0.0090 　 0.1682 0.0470 0.0276 0.0196 0.0136 0.0090 
　 　 0.85 0.1124 0.0350 0.0208 0.0148 0.0104 0.0070 　 0.1196 0.0356 0.0210 0.0150 0.0104 0.0070 
　 　 0.90 0.0870 0.0276 0.0164 0.0118 0.0082 0.0056 　 0.0908 0.0280 0.0166 0.0118 0.0082 0.0056 
Note: A lower value is presented when there are two  values satisfying  or .
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Figure 3. Scatter plot of  (or ) vs 
when ,  , ∆  and ∆ 
  Another property of  is the existence of outliers. The outlier is 
observed regardless of  or , especially in greater frequency 
when  and the effect sizes of ∆ and ∆ are greater. Since this 
thesis focuses on the application of  and , considering the regional 
type II error rate in actual clinical trial conditions, the cause of such 
outliers were not further investigated. Further research is needed to 
study the causes of the outliers. In Figure 4, outliers are highlighted 
in red dotted circles.
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Figure 4.  outliers when ,  , ∆ , ∆ 
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5.4. Regional type I error rate according to the effect size
  
  In this section, regional type I error rates  and  are 
calculated in relation to the changes in the effect sizes of the region 
of interest ∆ and other regions ∆ according to the similarity 
criterion (i) and (ii) as well as  and  values. Also, the changing 
pattern of  and  from the changes in parameter is investigated 
and the relationship between the regional type I error rate and the 
assurance probability proposed by Ko et al. (2010) is confirmed. 
5.4.1. Conditions for calculating  and 
  Regional type I error rates  and  were obtained by changing 
the ranges of , , , ∆ and ∆ according to similarity 
criteria. The ranges used to calculate  and  are as follows. The range 
of the effect size was 0.1-1.5 with 0.1 unit change and the overall 
sample size for each group  was 100-1,000 with 100 unit change. 
The range of the critical value  for the similarity was 0.5-0.9 with 
0.1 unit change and the proportion of number of patient for the 
clinical trial in the region of interest  was 0.1-0.9 with 0.1 unit 
change.
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[Summary of  and  calculation conditions]
(1) 
(2) Effect size: ≤∆ ∆≤ (∆≥∆ ), 0.1 unit change 
(3) ≤≤, 100 unit change
(4) ≤≤, 0.1 unit change
(5) ≤ ≤, 0.1 unit change
5.4.2.  and  according to the effect size
  The regional type I error rate calculated from changes in the effect 
sizes of the region of interest and other regions, ,  and  are not 
all listed in this thesis due to limited space. However, Table 6 shows 
an example of  and  values for when  is 500,  is 0.8, 0.9, 
∆ is 0.2-0.6, ∆ is 0.2-0.4, and  is 0.1-0.9. The first row 
shows the regional type I error rate according to  when the 
significance level is 0.025,  is 0.8 and effect sizes ∆ and ∆
are 0.2. If  is 0.1,  and  are 0.42 and 0.41, respectively. Table 
6 shows that in every case,  is smaller than . Especially if  is 
small,   and  are similar but as  increases  becomes much 
smaller than . In other words, if all other parameters are the 
same, respectively, as the proportion of patients for clinical trial in 
the region of interest  increases, the regional type I error rate 
according to the similarity criterion (ii) decreases. Therefore, the 
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possibility of error resulting in the incorrect conclusion that there is a 
difference in treatment effects despite the similar treatment effects, is 
reduced when assessing the similarity for the effect size of the region 
of interest. In contrast, if the regional type II error rate in section 5.1 
is used and all parameter conditions are the same, respectively, the 
similarity criterion (i) is less likely than the similarity criterion (ii) to 
make the wrong conclusion that the treatment effect in the region of 
interest is similar to that of other regions when it is not. 
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Table 6. The regional type I error rate when 
 
∆

∆
 :  　  : 
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 　 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 
0.8 0.2 0.2 0.42 0.39 0.37 0.36 0.35 0.35 0.36 0.37 0.40 　 0.41 0.37 0.33 0.29 0.25 0.21 0.16 0.10 0.03 
　 　 0.3 0.25 0.18 0.14 0.12 0.11 0.11 0.12 0.15 0.21 　 0.24 0.16 0.11 0.08 0.06 0.04 0.03 0.01 0.00 
　 　 0.4 0.12 0.06 0.03 0.02 0.02 0.02 0.02 0.04 0.08 　 0.12 0.05 0.02 0.01 0.01 0.00 0.00 0.00 0.00 
　 　 0.5 0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.02 　 0.05 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
　 　 0.6 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 　 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
　 0.3 0.3 0.39 0.35 0.32 0.31 0.30 0.30 0.31 0.33 0.36 　 0.38 0.32 0.27 0.22 0.18 0.13 0.08 0.04 0.01 
　 　 0.4 0.22 0.15 0.11 0.09 0.08 0.08 0.09 0.12 0.18 　 0.21 0.13 0.08 0.05 0.03 0.02 0.01 0.00 0.00 
　 　 0.5 0.10 0.04 0.02 0.01 0.01 0.01 0.01 0.03 0.07 　 0.10 0.04 0.01 0.01 0.00 0.00 0.00 0.00 0.00 
　 　 0.6 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02 　 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
　 0.4 0.4 0.35 0.30 0.27 0.25 0.24 0.24 0.25 0.27 0.32 　 0.34 0.26 0.21 0.15 0.11 0.07 0.03 0.01 0.00 
　 　 0.5 0.19 0.12 0.08 0.07 0.06 0.06 0.07 0.09 0.15 　 0.18 0.10 0.05 0.03 0.02 0.01 0.00 0.00 0.00 
　 　 0.6 0.09 0.03 0.02 0.01 0.01 0.01 0.01 0.02 0.05 　 0.08 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
0.9 0.2 0.2 0.46 0.45 0.44 0.43 0.43 0.43 0.43 0.44 0.46 　 0.46 0.43 0.41 0.39 0.37 0.34 0.30 0.25 0.16 
　 　 0.3 0.28 0.22 0.18 0.17 0.16 0.16 0.17 0.20 0.27 　 0.28 0.21 0.17 0.14 0.12 0.10 0.09 0.07 0.04 
　 　 0.4 0.15 0.08 0.05 0.04 0.03 0.04 0.04 0.07 0.13 　 0.14 0.07 0.04 0.03 0.02 0.02 0.01 0.01 0.00 
　 　 0.5 0.06 0.02 0.01 0.01 0.00 0.00 0.01 0.01 0.05 　 0.06 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
　 　 0.6 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 　 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
　 0.3 0.3 0.44 0.42 0.41 0.40 0.40 0.40 0.41 0.42 0.44 　 0.44 0.41 0.38 0.35 0.32 0.28 0.24 0.18 0.09 
　 　 0.4 0.27 0.20 0.17 0.15 0.14 0.14 0.16 0.19 0.25 　 0.26 0.19 0.14 0.11 0.09 0.07 0.05 0.04 0.01 
　 　 0.5 0.14 0.07 0.04 0.03 0.03 0.03 0.04 0.06 0.12 　 0.13 0.06 0.03 0.02 0.01 0.01 0.01 0.00 0.00 
　 　 0.6 0.06 0.02 0.01 0.00 0.00 0.00 0.01 0.01 0.04 　 0.06 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 
　 0.4 0.4 0.42 0.40 0.38 0.37 0.37 0.37 0.38 0.39 0.42 　 0.42 0.38 0.34 0.30 0.26 0.22 0.17 0.11 0.03 
　 　 0.5 0.25 0.18 0.15 0.13 0.12 0.12 0.14 0.17 0.23 　 0.25 0.17 0.12 0.09 0.07 0.05 0.03 0.02 0.00 
　 　 0.6 0.13 0.06 0.04 0.03 0.02 0.02 0.03 0.05 0.11 　 0.12 0.05 0.03 0.02 0.01 0.01 0.00 0.00 0.00 
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  Figures 5 and 6 show the relationship between the proportion of 
patients out of  in the region of interest  and the regional type I 
error rate.
       
∆   ∆     ∆   ∆    ∆   ∆  
Figure 5. Graph of the regional type I error rate vs 

when   and 
∆   ∆     ∆   ∆    ∆   ∆  
Figure 6. Graph of the regional type I error rate vs 

when   and 
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  As shown in Table 6 and Figures 5 and 6, if  and  are the same, 
respectively,  and  decrease as the difference between ∆ and 
∆ increases. On the other hand, if , ∆ and ∆ are the 
same, respectively, as  increases,  and  increase. In the 
similarity criterion (i), there is no case where  is lower than 20%, 
regardless of , in all cases where ∆ and ∆ are the same. 
However, in the similarity criterion (ii), as a  increases,  is lower 
than 20% after a certain . For example, if  , ∆∆ 
and  is greater than 0.62, then  is lower than 20%. Additionally, 
if ,  and  are the same, respectively, the regional type I error 
rate decreases as ∆∆ increases in both similarity criteria. 
Table 6 shows that when  is 0.8 and ∆∆ is 0.2, 0.3 and 0.4, 
 and  values are 0.42, 0.39, and 0.35 and 0.41, 0.38, and 0.34, 
respectively, demonstrating a decrease.
  The regional type I error rate related to the similarity criterion (ii) 
continuously decreases as  increases. As stated by Ko et al. (2010), 
this makes intuitive sense, since the observed overall treatment effect 
 will be increasingly dominated by the observed result from the 
region of interest , as  increases. On the contrast, the regional 
type I error rate related to the similarity criterion (i) decreases as 
increases and then decreases after a certain value of . As 
mentioned as a property of the assurance probability by Ko et al.  
(2010), this phenomenon arises from the fact that the observed result 
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from regions other than the region of interest  is gradually 
dominated by  at first, and is then overwhelmingly dominated by 
later as  increases.
  The method for controlling the regional type I error rate when 
∆  ∆ is the same as the assurance probability method by Ko 
et al. (2010). Ko et al. (2010) used the equation (16) which is the 
formula for calculating the sample size and applied the conversion of 
  into  , when deriving the assurance probability. 
Therefore, if  and  are the same, respectively, the effect size 
for the pre-determined  can be calculated and using this effect size, 
 and  can be calculated to obtain the same results as 
and  by Ko et al. (2010). This can be verified by using the 
formula for deriving the assurance probability and the formula for 
deriving the regional type I error rate, as shown in Appendix G.
  Table 7 shows the calculated  and  using the same 
parameters as in Table 1 of the study by Ko et al. (2010). These 
values were compared to  and . In order to calculate the 
regional type I error rate,  was assumed to be 100 and 500, and the 
effect size that type II error is 20% under   was calculated 
using the equation (16). In conclusion, if the assurance probability 
proposed by Ko et al. (2010) is subtracted from 1, it can be confirmed 
that it is exactly the same as the regional type I error rate. Therefore, 
the method by Ko et al. (2010) is a method to control the regional 
type I error rate, which is limited to cases where the effect size of the 
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region of interest is the same as that of other regions. On the other 
hand, the method using the regional type I error rate can be used for 
cases where the effect size of the region of interest is not only the 
same as that of other regions but also different from that of other 
regions excluding the region of interest. Therefore, this method is an 
expansion on the method proposed by Ko et al. (2010). 
Table 7. ,  and ,  when ,  ,  
    
     
      
0.05 0.7146 0.2854 0.7165 0.2835 0.2854 0.2835 0.2854 0.2835 
0.10 0.7899 0.2101 0.7948 0.2052 0.2101 0.2052 0.2101 0.2052 
0.15 0.8396 0.1604 0.8476 0.1524 0.1604 0.1524 0.1604 0.1524 
0.20 0.8757 0.1243 0.8863 0.1137 0.1243 0.1137 0.1243 0.1137 
0.25 0.9029 0.0971 0.9157 0.0843 0.0971 0.0843 0.0971 0.0843 
0.30 0.9239 0.0761 0.9383 0.0617 0.0761 0.0617 0.0761 0.0617 
0.35 0.9402 0.0598 0.9557 0.0443 0.0598 0.0443 0.0598 0.0443 
0.40 0.9531 0.0469 0.9691 0.0309 0.0469 0.0309 0.0469 0.0309 
0.45 0.9633 0.0367 0.9791 0.0209 0.0367 0.0209 0.0367 0.0209 
0.50 0.9713 0.0287 0.9866 0.0134 0.0287 0.0134 0.0287 0.0134 
0.55 0.9775 0.0225 0.9919 0.0081 0.0225 0.0081 0.0225 0.0081 
0.60 0.9824 0.0176 0.9955 0.0045 0.0176 0.0045 0.0176 0.0045 
0.65 0.9862 0.0138 0.9978 0.0022 0.0138 0.0022 0.0138 0.0022 
0.70 0.9890 0.0110 0.9991 0.0009 0.0110 0.0009 0.0110 0.0009 
0.75 0.9909 0.0091 0.9997 0.0003 0.0091 0.0003 0.0091 0.0003 
0.80 0.9921 0.0079 0.9999 0.0001 0.0079 0.0001 0.0079 0.0001 
0.85 0.9923 0.0077 1.0000 0.0000 0.0077 0.0000 0.0077 0.0000 
0.90 0.9904 0.0096 1.0000 0.0000 0.0096 0.0000 0.0096 0.0000 
Note: 
∆

∆
 when , 
∆

∆
 when 
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Chapter 6. Examples
6.1. Determination of  that satisfies the pre-determined 
regional type II error
  A randomized, multi-center, double-blind, parallel group, placebo- 
controlled clinical trial is to be planned to confirm the effects of the 
SGLT-2 drug on type II diabetes patients with difficulties controlling 
their blood glucose levels. Korea, Japan, and China will participate in 
the trial and the efficacy will be assessed according to the changes 
after 24 weeks of administration based on HbA1c levels in the blood 
samples.
  Based on the results observed from previous exploratory study, the 
total sample size is set to be 1,000, resulting in 500 for each group. 
The sample size to be allocated to Korea among 1,000 patients is 
planned to be 300 patients, which is 30% of the total patients. The 
primary purpose of this trial is to assess whether the efficacy result 
for Koreans is similar to that of other countries, as well as to assess 
the overall efficacy. The similarity between the Korean result and the 
result of other countries is accessed using the similarity criterion (i). 
To determine , the effect size of HbA1c change in Korea (∆) and 
the effect size of HbA1c change in Japan and China (∆) are 
assumed to be 0.4 and 0.7, respectively, and the regional type II error 
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rate to be 20%. The obtained value of  using these parameters is 
0.72 and this value will be used as a standard for assessing the 
similarity between result in Korea and that of other countries. 
6.2. Determination of the sample size in the region of 
interest using the regional type II error
  A multi-regional phase III clinical trial to assess the efficacy of 
inhaled corticosteroid (ICS) and long acting beta-agonist (LABA) on 
patients over 40 years of age with severe chronic obstructive 
pulmonary disease is to be planned. To assess the efficacy of an ICS 
+ LABA combination drug, a randomized, double-blind, parallel group, 
placebo-controlled clinical trial will be conducted using a dry power 
inhaler for drug delivery. The primary endpoint is the changes in 
FEV1 measured 60 minutes later after the administration of 
investigational product, and Five countries including Korea, Japan, 
China, Taiwan and Malaysia will participate in the trial. The effect size 
(∆) of the difference between the treatment and placebo groups is 
0.20501 in the phase II clinical trial conducted in two countries before 
this phase III trial. Using this result, the total sample size for the 
phase III clinical trial is calculated to be 1,000 (500 patients per group) 
at a significance level of 0.025 (one-sided) and 90% power. 
  The purpose of this trial is to examine whether the overall 
treatment effect from the MRCT can be applied to Korea, in addition 
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to demonstrate the overall treatment effect. Therefore, it is necessary 
to verify whether the overall treatment effect can be applied to Korea, 
under the condition that overall treatment effect is statistically 
significant. In this regard, the proportion of the patients recruited in 
Korea needs to be determined at the design phase of the trial to 
ensure the similarity between Korea and all regions.
  For assessment, similarity criterion (ii)   with   is used. 
And the effect size in Korea (∆) is assumed to be 0.1, and the 
effect size in all countries excluding Korea (∆) to be 0.25. Under 
these conditions, the proportion of patients recruited in Korea  is 
0.2516 so that the regional type II error rate will be 20%. And thus 
the required sample size in Korea per group is at least 500 × 0.2516 
≃ 126, corresponding to a total of 252 patients for the trial. 
6.3. Determination of the sample size in the region of 
interest using the regional type I error
  The method to determine the required sample size in the region of 
interest using the regional type I error rate is similar to the method 
proposed by Ko et al. (2010) using the assurance probability. The 
method by Ko et al. (2010) is a method to determine the sample size 
in the region of interest using , where the assurance probability is 
over a certain value, when the treatment effect is uniform across 
regions. On the other hand, the method using the regional type I 
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error rate can calculate the sample size in the region of interest using 
, where the regional type I error rate is lower than a certain value, 
even when the effect size in the region of interest is the same or 
greater than that of other regions.  
  Below, a similar example to those suggested in the published paper 
by Ko et al. (2010) is described. It is based on a calculation example 
using the regional type I error rate to determine the required sample 
size in the region of interest. 
  A randomized, double-blind, multi-regional clinical trial will be 
conducted in patients with hypercholesterolemia, atherosclerotic or 
coronary artery disease for comparing a new drug for lowering 
low-density-lipoprotein cholesterol (LDL-C) and a placebo control. In 
this trial, patients of age 18 years or older with documented LDL-C 
level between 2.5 mmol/L and ≤4.20 mmol/L are planned to be 
recruited from 3 regions including Taiwan, the United States and 
Europe. The primary efficacy variable is the percent change from 
baseline in LDL-C. The total sample size is calculated based on the 
results observed from previous exploratory study. The effect size of 
the primary endpoint (percent change in LDL-C) in the previous study 
was 0.228. Using this result, the total sample size is calculated to be 
1,000 (500 patients per group) at a significance level of 0.025 
(one-sided) and 95% power.
  In addition to demonstrate an overall treatment effect from all 
regions, this trial is also interested in examining whether the overall 
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results from the MRCT can be applied to Taiwan under the condition 
that the overall treatment effect is statistically significant in the 
overall region. In this regard, the proportion of the patients recruited 
in Taiwan needs to be determined at the design phase of the trial to 
ensure the similarity between Taiwan and all regions.
  If similarity criterion (ii) is used and  , ∆  and 
∆  are chosen, then the proportion of the patients recruited in 
Taiwan needs to be at least 0.34 so that the regional type I error rate 
will be at most 10%. In this case, the required total sample size from 
Taiwan is around 340 (170 patients per group). On the other hand, if 
 , then the required proportion of patients in Taiwan will 
increase to 0.6. That is, the total sample size of patients recruited 
from Taiwan needs to be at least 600 (300 patients per group).
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Chapter 7. Conclusion and discussion
  The benefits of MRCTs include the use of the same protocol in 
various regions to conduct clinical trials, such that the new drug can 
be approved simultaneously in multiple regions, thus saving time and 
costs. If the overall treatment effect of MRCTs is significant, it is 
essential to confirm that there is no ethnic difference in treatment 
effects. In general, the interaction between treatment and regions was 
tested to identify the existence of ethnic differences. However, to 
evaluate the interaction effects, a very large sample size is needed, 
and thus the numbers involved can make it unrealistic to conduct a 
trial (Uesaka, 2009). Currently, Japan is the only country with a 
regulatory body that provides a guideline on assessing consistency 
between regions in MRCTs which is mentioned in  the 11th Q&A to ICH 
E5. But there has been no research on the similarity criterion 
provided by MHLW in Japan as a decision process in terms of 
statistical hypothesis testing. 
  Ko et al. (2010) proposed the assurance probabilities based on the 
MHLW guideline to calculate the sample size in the region of interest. 
However, the assurance probability by Ko et al. (2010) is not 
appropriate in that it focuses on the alternative hypothesis that the 
overall treatment is significant, which is related to the first of two 
objectives in a MRCT.  
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  This thesis introduced a method standardized by effect size, which 
was originally suggested by Kang et al. (2016), as a statistical 
hypothesis testing procedure to address the second purpose of MRCTs. 
This thesis also discussed approaches using the regional type II error 
rate to calculate critical values for a hypothesis testing on the 
similarity, as well as the required number of clinical trial subjects in 
the region of interest through the suggested method. 
  The results of this thesis demonstrate a difference in the regional 
type II error rate according to the similarity criteria. And when an 
effect size, a critical value and other parameters are the same, 
respectively, the regional type II error rate of the similarity criterion 
 ≥  is smaller than that of the similarity criterion  ≥  . In 
particular, if the number of patients in the region of interest in a 
MRCT is very large, choosing the similarity criterion  ≥  is a 
way to reduce the regional type II error rate. The regional type II 
error rate is easier to control when the difference between effect sizes 
in the region of interest and other regions is great or the critical 
value for similarity is great. 
  The selection of critical value  is extremely important in assessing 
the similarity between the data from the region of interest and in all 
regions. Currently, the Japanese MHLW is the only regulatory authority 
that provides a condition for critical value, which is over 0.5. This 
thesis introduced a method to determine the critical value of the 
similarity assessment using the statistical hypothesis testing procedure 
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by controlling the regional type II error rate. As a result, if the 
regional type II error rate is pre-determined and parameters such as 
the effect sizes and the proportion of patients in the region of interest 
are the same, respectively, the critical value for the similarity 
criterion  ≥  is greater than that of  ≥  . In other words, 
the second similarity criterion is more conservative in assessing the 
similarity than the first criterion. Furthermore, regardless of the 
similarity criteria, if the regional type II error rate is pre-determined 
and other parameters are the same, respectively, as the difference in 
effect size between the region of interest and other regions increases, 
the critical value for the similarity becomes smaller. In the method 
presented in this thesis, this phenomenon means the following. 
Suppose that the MRCT should be conducted even if there is a large 
difference between the region of interest and other regions which is 
not clinically meaningful. In this case, the critical value in the method 
to control the regional type II error becomes relatively small and thus 
increases the likelihood of proving the similarity. 
  As confirmed in the results of this thesis, in cases using a certain 
combination of parameters according to similarity criteria, the regional 
type II error rate is never lower than the pre-determined level, such 
as 20%. For example, if the effect size in the region of interest is 
comparable to that of other regions, the regional type II error rate is 
maintained at a considerably high level. In such cases where 
treatment effects are assumed to be similar, the regional type II error 
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rate cannot be maintained at low levels. And consequently, there is 
high likelihood of the incorrect conclusion that there is no difference 
in treatment effects, despite the difference in treatment effects in all 
participating regions and the region of interest. Even if it is evaluated 
that there is a statistically significant difference of the effect size 
despite a slight difference, this slight difference can be evaluated as 
the similarity of the treatment effects in actual clinical situations.
Therefore, this error is not a major problem in applying the regional 
type II error rate.   
  It may seem reasonable that as the proportion of the patients in the 
region of interest increases, the regional type II error rate decreases. 
However, there is no monotone decrease in the regional type II error 
rate with the proportion of the patients in the region of interest. In 
light of this property, it may not be appropriate to use the regional 
type II error rate method with the similarity criteria of the Japanese 
MHLW and those suggested by Ko et al. (2010). That is why there is a 
need for new studies to develop similarity criteria that satisfy the 
monotonically decreasing relationship between the regional type II 
error rate and the proportion of the patients in the region of interest. 
In summary, it is important to develop and apply the best similarity 
criteria, in order to select the proportion of patients in the region of 
interest using the regional type II error rate or to determine the 
critical value for the similarity assessment, as suggested in this thesis. 
  If the effect size is uniform across regions, the method to control 
the regional type I error rate is the same as that using the assurance 
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probability method proposed by Ko et al. (2010). Since the method to 
control the regional type I error rate can also be used in cases where 
effect sizes across regions are heterogeneous, it is an expanded form 
of the method by Ko et al. (2010) and it can be utilized in various 
clinical trial environments. Under the clinical trial condition where 
parameters such as ,  and  are the same, respectively, the 
regional type I error rate in the similarity criterion (ii) is smaller than 
that of the similarity criterion (i). In other words, it means that using 
the similarity criterion (ii) is less likely to make the wrong conclusion 
that the treatment effect in the region of interest is not similar to that 
of all regions when it is similar. Furthermore, as the proportion of the 
patients in the region of interest  increases, the regional type I 
error rate for similarity criterion (ii) decreases, thus the likelihood of 
the wrong conclusion that there is no similarity when there is the 
actual similarity of the treatment effects in the region of interest, is 
reduced.
  This thesis includes a comparison between methods to control the 
regional type I error and regional type II error. Regional type II error, 
which leads to the incorrect conclusion that there is no difference 
when there is a difference in treatment effects between ethnic groups, 
is more critical. From the perspective of regulatory authorities, an 
incorrect conclusion that claims the similarity when there is a 
difference in treatment effects between ethnic groups is more serious, 
because it results in drug approval. On the other hand, for new drug 
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developers, an incorrect conclusion that there is a difference when 
there is no difference in treatment effects between ethnic groups leads 
to a delay in market approval and additional developmental processes 
resulting in greater consumption of resources and time. The method 
suggested in this thesis to use the regional type I error and the 
regional type II error independently can only satisfy one party. This 
being so, there is a need for further studies that minimize both 
regional type I error and regional type II error, in order to satisfy 
both parties, the regulatory bodies and the pharmaceutical company.
  In this thesis, the regional error rate was applied by setting the null 
and alternative hypotheses for the second purpose of MRCTs as 
“There is the similarity in treatment effects between regions” and 
“There is no similarity in treatment effects between regions”, 
respectively. The alternative hypothesis that claims no similarity 
focuses on the aim to confirm that there is a possibility of difference 
between regions that may or may not exist when the similarity is 
predicted. But the hypothesis for the second purpose of MRCTs can be 
expressed in various forms. A hypothesis with the opposite concept to 
the secondary hypothesis proposed in this thesis can be used to 
assess the similarity between regions, and the regional error rate 
using this hypothesis can be used to determine the critical value for 
the similarity assessment and the number of patients in the region of 
interest. Under the conditions of this hypothesis, the regional type I 
error is more critical than the regional type II error, and thus the 
regional type I error should be the primary concern in assessing the 
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required parameters. The limitation of this thesis is not only that the 
properties of the regional error rate are not investigated under the 
alternative hypothesis that treatment effects between regions are 
similar, but also the results with those in this thesis are not 
compared. Such results of comparisons and assessments need to be 
confirmed through follow-up studies.
  Recently, there has been a trend towards globalization in new drug 
development using MRCTs in Korea. As the frequency of conducting 
MRCTs increase, it becomes more important to determine the number 
of patients assigned to the region of interest, for example, Korea, as 
well as the critical value to assess the similarity in treatment effects 
between regions. Previous studies have investigated the required 
sample size in the region of interest in a MRCT. However, there are 
no studies that consider the statistical hypothesis testing procedure 
for the two purposes of the MRCT described in the ICH E5 guideline. 
Recently, the ICH has been conducting meetings with experts to 
provide a guideline for general principle on planning and designing 
MRCTs. The currently published guideline for MRCTs is a draft version 
for Step 2. According to this draft guideline, there is a need for a 
appropriate plan for sample size allocation to describe the treatment 
effects in the multi-regional setting, when there may be some 
variations in treatment effect due to different distributions of intrinsic 
and extrinsic factors among regions. This draft guideline also 
describes that there are several approaches to allocate the overall 
sample size to regions considering some variation in treatment effect 
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and one of them is described as follow (ICH E17, 2916). “One approach 
is to determine the sample size needed in one or more regions based 
on the ability to show that the region-specific treatment effect 
preserves some pre-specified proportion of the overall treatment 
effect”. Although this is a draft version, the method mentioned in ICH 
E17 focuses on sample size allocation in an environment where the 
application of similarity criteria and the treatment effects between 
regions are not homogeneous. Therefore, there is a need for various 
statistical methods for MRCT that is applicable to not only the two 
purposes of MRCT mentioned above, but also to a heterogeneous 
environment of the treatment effects between regions. The method 
propose in this thesis reflects the statistical hypothesis testing 
procedure for two purposes of MRCTs as mentioned in ICH E5, and 
allows calculation of the critical value for the similarity assessment, as 
well as the number of patients in the region of interest even when 
there is a difference in treatment effects between regions. Therefore, 
it can be said that this study considers recent topics of interest 
concerning MRCTs. Considering the recent increase in frequency of 
conducting MRCTs, there is a need for further research on various 
methods using regional type errors and such methods are expected to 
be useful in the actual environment of MRCTs.
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Appendix
Appendix A : Relationship between the overall treatment effect and the 
regional treatment effects
Let  be the total number of participating regions and  be the total 
number of patients in the th region (   ⋯). The Difference in 
the treatment effects between the test product and the placebo in all 
participating regions (∆) can be expressed as follows.
  ∆    
 

 




  

   
 


  

  
 

 





  

  


 



 




 



 


  

  
 ∆  ∆
where
 

 



,  ∆ 

  

  
,  ∆ 

 



 


  

  
- 74 -
Appendix B : The derivation of regional type II error rate
The derivation of  is as follows.
   ≥        ∆∆  
  ≥ 



         
     




∆
≥ 








∆

 


 




∆





∆
   




∆

 




∆
   




∆





∆
  
       ≥ 



 




∆
 
∆
     
  




∆
 
∆
 
     ≥         
        
 ≥          
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   

∞
∞
  

  




∞


  

  

  


where
  



,    




∆
 
∆
 ,     ,     ,
  




∆
 
∆
 ,       
  
  
The derivation of  is as below.
  

 

,    

  




  
⇒           
⇒    
  
    
  
 
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Similarly, the derivation of  is as follows.
   ≥        ∆∆ 
  ≥         
  ≥

      
  ≥

         
     




∆
≥

 




∆


 




∆





∆
   




∆

   
      




∆
   




∆





∆
  
    
     ≥


 




∆





∆
   




∆
 
∆
 
     ≥          
      
 ≥         
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   

∞
∞
  

  




∞


  

  

  


where
  

,    




∆





∆
,     ,  
   ,    




∆
 
∆
 ,       
  
  
The derivation of  is as below.
  

 

,    

 




  
⇒           
⇒    
  
    
  
 
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No
FDA
approv
al year
Active
Ingredient
Study name Dose
Treatment  - 
Placebo |Effect 
size|
Mean SD
1
2011
ARCPTA
B2336
Ind  150 mcg 0.17 0.36 0.48 
Salmeterol 0.11 0.36 0.31 
B2354 Ind  75 mcg 0.12 0.12 0.98 
B2355 Ind  75 mcg 0.14 0.24 0.58 
2 BUPIVACAINE
SKY0402-C-316 300mg -60.00 106.37 0.56 
SKY0402-C-317 120mg -21.00 44.53 0.47 
3
GABAPENTIN  
ENACARBIL
XP052 1200mg -4.48 8.93 0.50 
XP053 600mg -3.98 7.91 0.50 
XP060 1200mg -3.11 8.49 0.37 
4 CLOBAZAM
STUDY  
OV-1012
0.25mg 29.10 61.60 0.47 
0.5mg 35.30 67.51 0.52 
1mg 57.00 59.78 0.95 
5 CELLEGESIC REC-C-001 - -5.00 33.90 0.15 
6 VILAZODONE
CLDA-07-DP-02 40mg/day -2.50 20.59 0.12 
GNSC-04-DP-02 40mg/day -3.20 19.06 0.17 
7
2012
LORCASERIN
STUDY  009 10mg bid -3.70 6.21 0.60 
STUDY 010
10mg bid -3.10 6.32 0.49 
10mg qd -3.10 3.69 0.84 
STUDY 011
10mg bid -3.00 7.88 0.38 
10mg qd -1.90 7.17 0.27 
8 MP29-02
MP4002 - -2.70 4.16 0.65 
MP4004 - -2.42 4.28 0.56 
MP4006 - -2.16 4.35 0.50 
9
LINAGLIPTIN
STUDY 46
5mg -0.60 1.06 0.57 
2.5mg/500mg 
Twice
-1.30 1.07 1.22 
METFORMIN
500mg -0.70 1.08 0.65 
1000mg Twice -1.10 1.07 1.03 
LINAGLIPTIN
&METFORMIN
2.5mg+1000mg  
Twice
-1.70 1.08 1.58 
10 PREGABALIN
STUDY  125 - -1.46 1.92 0.76 
STUDY 1107 - -0.59 1.46 0.41 
11
BECLOMETHASO
NE
DIPROPIONATE
STUDY  301 320mcg -1.00 2.01 0.50 
STUDY 302 320mcg -0.90 2.14 0.42 
STUDY 303 320mcg -1.00 2.25 0.44 
12
PHENETERMINE
OB-301
7.5mg -3.90 6.03 0.65 
　 46mg -3.50 6.03 0.58 
　
TOPIRAMATE
15mg -4.30 6.10 0.70 
　 92mg -4.80 6.09 0.79 
　
PHENETERMINE 
& TOPIRAMATE
7.5mg+46mg -7.10 6.00 1.18 
　 15mg+92mg -7.70 6.04 1.27 
Appendix C : Table A1. Result of the effect size through literature 
reviews
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No
FDA
approv
al year
Active
Ingredient
Study name Dose
Treatment  - 
Placebo |Effect 
size|
Mean SD
　
PHENETERMINE 
& TOPIRAMATE
OB-302
15mg+92mg -9.90 8.82 1.12 
　 3.75mg+23mg -3.70 8.43 0.44 
　
OB-303
15mg+92mg -8.60 6.20 1.39 
　 7.5mg+46mg -6.50 6.32 1.03 
13
METHYLPHENID
ATE HCL
NWP06-ADD-100 - -12.10 7.14 1.69 
14
ACLIDINIUM 
BROMIDE
M33
200ug 0.09 0.20 0.42 
400ug 0.12 0.20 0.62 
M38a
200ug 0.05 0.20 0.25 
400ug 0.07 0.21 0.35 
15 PANCRELIPASE VIO16EPI07-01 - 36.50 21.44 1.70 
16
2013
RIOCIGUAT
STUDY 12934
1.0-2.5mg 35.20 72.91 0.48 
1.0-1.5mg 36.70 83.50 0.44 
STUDY 11348 1.0-2.5mg 44.40 81.01 0.55 
17
PAROXETINE 
MESYLATE
STUDY-003
7.5mg -1.35 4.34 0.31 
7.5mg -0.05 0.24 0.19 
STUDY 004
7.5mg -1.42 4.17 0.34 
7.5mg -0.03 0.23 0.14 
18
CANAGLIFLOZIN DIA3005
100mg -0.91 0.83 1.10 
300mg -1.17 0.83 1.41 
CANAGLIFLOZIN
METFORMIN
DIA3006
100mg -0.62 0.78 0.80 
300mg -0.77 0.78 0.99 
19 MIPOMERSEN
ISIS  
301012-CS5
200mg -21.40 18.98 1.13 
MIPO3500108 200mg -48.40 33.18 1.46 
ISIS 301012-CS7 200mg -33.20 24.39 1.36 
ISIS 
301012-CS12
200mg -32.40 26.01 1.25 
20
OSPEMIFENE 15-50310 60mg
-0.50 1.16 0.43 
8.15 13.41 0.61 
-40.28 25.77 1.56 
-0.97 0.95 1.02 
OSPEMIFENE 15-50821 60mg
-0.26 1.13 0.23 
10.66 11.84 0.90 
-40.01 27.32 1.46 
-0.87 0.86 1.01 
21 POLIDOCANOL
VAP-VV015 - -3.31 3.60 0.92 
VAP-VV016 - -3.53 3.54 1.00 
22
2014
BELSOMRA
STUDY 28
Low 8.20 55.92 0.15 
High 20.10 57.22 0.35 
STUDY 29
Low 23.90 61.46 0.39 
High 22.60 64.16 0.35 
23 CONTRAVE
NB-301
16mg -4.60 6.65 0.69 
32mg -4.80 6.65 0.72 
NB-302 32mg -4.20 8.66 0.49 
NB-303 32mg -4.60 5.99 0.77 
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No
FDA
approv
al year
Active
Ingredient
Study name Dose
Treatment  - 
Placebo |Effect 
size|
Mean SD
NB-304 32mg -3.20 4.94 0.65 
24 ESBRIET
STUDY  016 1 Capsule TID 2.90 6.70 0.43 
STUDY 004 1 Capsule TID 4.40 17.52 0.25 
STUDY 006 1 Capsule TID 0.60 19.35 0.03 
25 FARXIGA D1690C00019 10mg -0.40 1.01 0.40 
26 JARDIANCE
1245.23
10mg -0.59 0.73 0.81 
25mg -0.62 0.80 0.77 
10mg -0.62 0.75 0.83 
25mg -0.59 0.74 0.79 
1245.19
10mg -0.43 0.97 0.45 
25mg -0.56 0.97 0.58 
1245.20
10mg -0.72 0.75 0.96 
25mg -0.83 0.83 1.00 
27 TANZEUM GLP112755 30mg -0.76 0.87 0.88 
28 TARGINIQ ER OUN3701 OXN -0.50 1.73 0.29 
29 TIVORBEX
IND3_08_04b
40mg TID 442.00 887.14 0.50 
40mg BID 260.00 884.68 0.29 
20mg TID 313.00 884.68 0.35 
IND3-10-06
40mg TID 318.00 1027.71 0.31 
40mg BID 342.00 1024.99 0.33 
20mg TID 62.00 1027.02 0.06 
30
TRULICITY
GBCF_GBDF
0.75mg -1.04 0.98 1.06 
1.5mg -1.23 0.92 1.33 
SITAGLPTIN - -0.63 0.97 0.65 
TRULICITY
GBCF_GBDA
0.75mg -0.84 0.97 0.87 
1.5mg -1.05 0.97 1.08 
EXENATIDE 　 -0.53 0.97 0.55 
31 XARTEMIS XR STUDY 0182
OC/APAP  
7.5mg/325mg
48.00 86.16 0.56 
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
or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
0.10 0.40 0.60 　 　 　 1.00 0.97 0.95 0.94 0.93 0.92 0.92 　 　 　 　 1.00 0.98 0.97 0.96 0.96 0.96 0.96 
　 　 0.65 　 　 0.96 0.92 0.89 0.87 0.86 0.85 0.85 0.84 　 　 　 0.96 0.93 0.92 0.91 0.90 0.91 0.91 0.91 
　 　 0.70 　 0.95 0.88 0.85 0.82 0.81 0.79 0.79 0.78 0.77 　 　 0.95 0.90 0.87 0.86 0.86 0.86 0.86 0.87 0.87 
　 　 0.75 　 0.88 0.82 0.79 0.77 0.75 0.74 0.73 0.72 0.72 　 　 0.89 0.85 0.82 0.81 0.81 0.81 0.82 0.83 0.84 
　 　 0.80 0.95 0.83 0.77 0.74 0.72 0.70 0.69 0.68 0.67 0.67 　 0.96 0.84 0.80 0.78 0.77 0.77 0.77 0.78 0.79 0.80 
　 　 0.85 0.90 0.78 0.72 0.69 0.67 0.66 0.65 0.64 0.63 0.63 　 0.90 0.79 0.75 0.74 0.73 0.73 0.74 0.75 0.76 0.77 
　 　 0.90 0.85 0.73 0.68 0.65 0.63 0.62 0.61 0.60 0.59 0.59 　 0.85 0.75 0.72 0.70 0.70 0.70 0.71 0.71 0.73 0.74 
　 0.45 0.65 　 　 　 1.00 0.97 0.96 0.94 0.94 0.93 0.93 　 　 　 　 1.00 0.98 0.97 0.96 0.96 0.96 0.96 
　 　 0.70 　 　 0.96 0.92 0.90 0.88 0.87 0.86 0.86 0.85 　 　 　 0.97 0.94 0.92 0.92 0.91 0.91 0.92 0.92 
　 　 0.75 　 0.95 0.89 0.86 0.84 0.82 0.81 0.80 0.80 0.79 　 　 0.96 0.91 0.88 0.87 0.87 0.87 0.87 0.88 0.88 
　 　 0.80 　 0.89 0.83 0.80 0.78 0.77 0.75 0.75 0.74 0.74 　 　 0.90 0.86 0.84 0.83 0.82 0.83 0.83 0.84 0.85 
　 　 0.85 0.96 0.84 0.78 0.75 0.73 0.72 0.71 0.70 0.69 0.69 　 0.96 0.85 0.81 0.79 0.79 0.78 0.79 0.80 0.81 0.82 
　 　 0.90 0.90 0.79 0.74 0.71 0.69 0.68 0.67 0.66 0.65 0.65 　 0.91 0.81 0.77 0.75 0.75 0.75 0.75 0.76 0.77 0.79 
　 0.50 0.70 　 　 　 1.00 0.98 0.96 0.95 0.94 0.94 0.93 　 　 　 　 1.00 0.98 0.97 0.97 0.96 0.96 0.97 
　 　 0.75 　 　 0.96 0.93 0.91 0.89 0.88 0.87 0.87 0.87 　 　 　 0.97 0.94 0.93 0.92 0.92 0.92 0.92 0.93 
　 　 0.80 　 0.95 0.90 0.87 0.85 0.83 0.82 0.81 0.81 0.81 　 　 0.96 0.91 0.89 0.88 0.88 0.88 0.88 0.89 0.89 
　 　 0.85 　 0.90 0.84 0.81 0.79 0.78 0.77 0.76 0.76 0.75 　 　 0.91 0.86 0.85 0.84 0.84 0.84 0.84 0.85 0.86 
　 　 0.90 0.96 0.85 0.80 0.77 0.75 0.73 0.73 0.72 0.71 0.71 　 0.96 0.86 0.82 0.81 0.80 0.80 0.80 0.81 0.82 0.83 
　 0.55 0.75 　 　 　 1.00 0.98 0.96 0.95 0.95 0.94 0.94 　 　 　 　 1.00 0.98 0.97 0.97 0.97 0.97 0.97 
　 　 0.80 　 　 0.96 0.93 0.91 0.90 0.89 0.88 0.88 0.87 　 　 　 0.97 0.95 0.93 0.93 0.92 0.93 0.93 0.93 
　 　 0.85 　 0.96 0.91 0.88 0.86 0.84 0.83 0.83 0.82 0.82 　 　 0.96 0.92 0.90 0.89 0.88 0.88 0.89 0.89 0.90 
　 　 0.90 　 0.90 0.85 0.83 0.81 0.79 0.78 0.78 0.77 0.77 　 　 0.91 0.87 0.86 0.85 0.85 0.85 0.85 0.86 0.87 
　 0.60 0.80 　 　 　 1.00 0.98 0.96 0.96 0.95 0.95 0.94 　 　 　 　 1.00 0.98 0.98 0.97 0.97 0.97 0.97 
　 　 0.85 　 　 0.97 0.94 0.92 0.90 0.90 0.89 0.88 0.88 　 　 　 0.97 0.95 0.94 0.93 0.93 0.93 0.93 0.94 
　 　 0.90 　 0.96 0.91 0.88 0.86 0.85 0.84 0.84 0.83 0.83 　 　 0.96 0.92 0.90 0.90 0.89 0.89 0.90 0.90 0.91 
　 0.65 0.85 　 　 　 1.00 0.98 0.97 0.96 0.95 0.95 0.95 　 　 　 　 1.00 0.99 0.98 0.97 0.97 0.97 0.97 
　 　 0.90 　 　 0.97 0.94 0.92 0.91 0.90 0.90 0.89 0.89 　 　 　 0.97 0.95 0.94 0.94 0.93 0.94 0.94 0.94 
　 0.70 0.90 　 　 　 1.00 0.98 0.97 0.96 0.96 0.95 0.95 　 　 　 　 1.00 0.99 0.98 0.97 0.97 0.97 0.98 
0.15 0.40 0.55 　 　 　 　 1.00 0.98 0.97 0.96 0.96 0.96 　 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 
　 　 0.60 　 　 0.97 0.93 0.91 0.89 0.88 0.88 0.87 0.87 　 　 　 0.97 0.94 0.93 0.92 0.92 0.92 0.92 0.93 
　 　 0.65 　 0.94 0.89 0.86 0.84 0.82 0.81 0.80 0.80 0.79 　 　 0.95 0.90 0.88 0.87 0.87 0.87 0.87 0.88 0.89 
　 　 0.70 0.99 0.87 0.82 0.79 0.77 0.76 0.75 0.74 0.74 0.73 　 0.99 0.89 0.85 0.83 0.82 0.82 0.82 0.83 0.84 0.85 
　 　 0.75 0.93 0.81 0.77 0.74 0.72 0.71 0.70 0.69 0.68 0.68 　 0.93 0.83 0.79 0.78 0.77 0.77 0.78 0.79 0.80 0.81 
　 　 0.80 0.87 0.76 0.72 0.69 0.67 0.66 0.65 0.64 0.64 0.64 　 0.87 0.78 0.75 0.74 0.73 0.74 0.74 0.75 0.76 0.78 
Appendix D : Table A2.  selection when =500
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
or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
　 　 0.85 0.82 0.72 0.67 0.65 0.63 0.62 0.61 0.60 0.60 0.60 　 0.82 0.74 0.71 0.70 0.70 0.70 0.71 0.72 0.73 0.75 
　 　 0.90 0.77 0.68 0.64 0.61 0.60 0.58 0.58 0.57 0.56 0.56 　 0.78 0.70 0.67 0.66 0.66 0.67 0.68 0.69 0.70 0.72 
　 0.45 0.60 　 　 　 　 1.00 0.98 0.97 0.97 0.96 0.96 　 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 
　 　 0.65 　 　 0.97 0.94 0.92 0.90 0.89 0.89 0.88 0.88 　 　 　 0.97 0.95 0.94 0.93 0.93 0.93 0.93 0.94 
　 　 0.70 　 0.95 0.90 0.87 0.85 0.83 0.83 0.82 0.81 0.81 　 　 0.95 0.91 0.89 0.88 0.88 0.88 0.88 0.89 0.90 
　 　 0.75 0.99 0.88 0.84 0.81 0.79 0.78 0.77 0.76 0.76 0.75 　 0.99 0.89 0.86 0.84 0.83 0.83 0.84 0.84 0.85 0.86 
　 　 0.80 0.93 0.83 0.78 0.76 0.74 0.73 0.72 0.71 0.71 0.70 　 0.93 0.84 0.81 0.79 0.79 0.79 0.80 0.80 0.81 0.83 
　 　 0.85 0.87 0.78 0.73 0.71 0.69 0.68 0.67 0.67 0.66 0.66 　 0.88 0.79 0.77 0.75 0.75 0.75 0.76 0.77 0.78 0.79 
　 　 0.90 0.83 0.73 0.69 0.67 0.65 0.64 0.63 0.63 0.62 0.62 　 0.83 0.75 0.73 0.72 0.72 0.72 0.73 0.74 0.75 0.77 
　 0.50 0.65 　 　 　 　 1.00 0.98 0.98 0.97 0.97 0.96 　 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 
　 　 0.70 　 　 0.97 0.94 0.92 0.91 0.90 0.89 0.89 0.89 　 　 　 0.98 0.95 0.94 0.94 0.93 0.93 0.94 0.94 
　 　 0.75 　 0.95 0.90 0.88 0.86 0.85 0.84 0.83 0.83 0.82 　 　 0.96 0.92 0.90 0.89 0.89 0.89 0.89 0.90 0.90 
　 　 0.80 0.99 0.89 0.85 0.82 0.80 0.79 0.78 0.78 0.77 0.77 　 0.99 0.90 0.87 0.85 0.84 0.84 0.85 0.85 0.86 0.87 
　 　 0.85 0.93 0.84 0.79 0.77 0.75 0.74 0.73 0.73 0.72 0.72 　 0.94 0.85 0.82 0.81 0.80 0.80 0.81 0.82 0.83 0.84 
　 　 0.90 0.88 0.79 0.75 0.73 0.71 0.70 0.69 0.69 0.68 0.68 　 0.89 0.81 0.78 0.77 0.77 0.77 0.78 0.78 0.80 0.81 
　 0.55 0.70 　 　 　 　 1.00 0.99 0.98 0.97 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.98 0.98 0.98 
　 　 0.75 　 　 0.97 0.95 0.93 0.92 0.91 0.90 0.90 0.90 　 　 　 0.98 0.96 0.95 0.94 0.94 0.94 0.94 0.95 
　 　 0.80 　 0.95 0.91 0.88 0.87 0.86 0.85 0.84 0.84 0.84 　 　 0.96 0.92 0.91 0.90 0.90 0.90 0.90 0.90 0.91 
　 　 0.85 0.99 0.90 0.86 0.83 0.79 0.80 0.80 0.79 0.79 0.78 　 0.99 0.91 0.87 0.86 0.85 0.85 0.86 0.86 0.87 0.88 
　 　 0.90 0.94 0.85 0.81 0.78 0.77 0.76 0.75 0.74 0.74 0.74 　 0.94 0.86 0.83 0.82 0.82 0.82 0.82 0.83 0.84 0.85 
　 0.60 0.75 　 　 　 　 1.00 0.99 0.98 0.97 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.98 0.98 0.99 
　 　 0.80 　 　 0.97 0.95 0.93 0.92 0.91 0.91 0.91 0.90 　 　 　 0.98 0.96 0.95 0.94 0.94 0.94 0.95 0.95 
　 　 0.85 　 0.96 0.92 0.89 0.88 0.87 0.86 0.85 0.85 0.85 　 　 0.96 0.93 0.91 0.90 0.90 0.90 0.91 0.91 0.92 
　 　 0.90 0.99 0.90 0.86 0.84 0.83 0.82 0.81 0.80 0.80 0.80 　 1.00 0.91 0.88 0.87 0.86 0.86 0.87 0.87 0.88 0.89 
　 0.65 0.80 　 　 　 　 1.00 0.99 0.98 0.98 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.85 　 　 0.98 0.95 0.94 0.93 0.92 0.91 0.91 0.91 　 　 　 0.98 0.96 0.95 0.95 0.95 0.95 0.95 0.95 
　 　 0.90 　 0.96 0.92 0.90 0.88 0.87 0.87 0.86 0.86 0.86 　 　 0.96 0.93 0.92 0.91 0.91 0.91 0.91 0.92 0.92 
　 0.70 0.85 　 　 　 　 1.00 0.99 0.98 0.98 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.90 　 　 0.98 0.96 0.94 0.93 0.92 0.92 0.92 0.92 　 　 　 0.98 0.96 0.96 0.95 0.95 0.95 0.95 0.96 
　 0.75 0.90 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
0.20 0.40 0.55 　 　 0.99 0.96 0.94 0.93 0.92 0.92 0.91 0.91 　 　 　 0.99 0.97 0.96 0.95 0.95 0.95 0.95 0.95 
　 　 0.60 　 0.96 0.91 0.88 0.86 0.85 0.84 0.83 0.83 0.83 　 　 0.96 0.92 0.90 0.89 0.89 0.89 0.89 0.90 0.91 
　 　 0.65 0.98 0.88 0.84 0.81 0.79 0.78 0.77 0.77 0.76 0.76 　 0.98 0.89 0.86 0.84 0.84 0.84 0.84 0.85 0.85 0.86 
　 　 0.70 0.91 0.82 0.77 0.75 0.73 0.72 0.71 0.71 0.70 0.70 　 0.92 0.83 0.80 0.79 0.79 0.79 0.79 0.80 0.81 0.82 
　 　 0.75 0.85 0.76 0.72 0.70 0.68 0.67 0.66 0.66 0.65 0.65 　 0.86 0.78 0.75 0.74 0.74 0.75 0.75 0.76 0.78 0.79 
　 　 0.80 0.80 0.71 0.68 0.65 0.64 0.63 0.62 0.62 0.61 0.61 　 0.81 0.73 0.71 0.70 0.70 0.71 0.72 0.73 0.74 0.76 
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
or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
　 　 0.85 0.75 0.67 0.64 0.61 0.60 0.59 0.58 0.58 0.57 0.57 　 0.76 0.69 0.67 0.67 0.67 0.67 0.68 0.70 0.71 0.73 
　 　 0.90 0.71 0.63 0.60 0.58 0.57 0.56 0.55 0.55 0.54 0.54 　 0.72 0.66 0.64 0.63 0.64 0.64 0.65 0.67 0.68 0.70 
　 0.45 0.60 　 　 0.99 0.97 0.95 0.94 0.93 0.92 0.92 0.92 　 　 　 1.00 0.97 0.96 0.96 0.95 0.95 0.95 0.96 
　 　 0.65 　 0.96 0.92 0.89 0.87 0.86 0.85 0.85 0.84 0.84 　 　 0.96 0.93 0.91 0.90 0.90 0.90 0.90 0.91 0.91 
　 　 0.70 0.99 0.89 0.85 0.82 0.81 0.80 0.79 0.78 0.78 0.78 　 0.99 0.90 0.87 0.85 0.85 0.85 0.85 0.86 0.87 0.87 
　 　 0.75 0.92 0.83 0.79 0.77 0.75 0.74 0.73 0.73 0.72 0.72 　 0.92 0.84 0.82 0.80 0.80 0.80 0.81 0.82 0.83 0.84 
　 　 0.80 0.86 0.78 0.74 0.72 0.70 0.69 0.69 0.68 0.68 0.67 　 0.87 0.79 0.77 0.76 0.76 0.76 0.77 0.78 0.79 0.81 
　 　 0.85 0.81 0.73 0.70 0.68 0.66 0.65 0.65 0.64 0.64 0.63 　 0.82 0.75 0.73 0.72 0.72 0.73 0.74 0.75 0.76 0.78 
　 　 0.90 0.76 0.69 0.66 0.64 0.62 0.61 0.61 0.60 0.60 0.60 　 0.77 0.71 0.69 0.69 0.69 0.70 0.70 0.72 0.73 0.75 
　 0.50 0.65 　 　 0.99 0.97 0.95 0.94 0.93 0.93 0.93 0.92 　 　 　 1.00 0.98 0.96 0.96 0.96 0.96 0.96 0.96 
　 　 0.70 　 0.96 0.92 0.90 0.88 0.87 0.86 0.86 0.86 0.85 　 　 0.97 0.93 0.92 0.91 0.91 0.91 0.91 0.92 0.92 
　 　 0.75 0.99 0.90 0.86 0.84 0.82 0.81 0.80 0.80 0.80 0.79 　 0.99 0.91 0.88 0.86 0.86 0.86 0.86 0.87 0.88 0.88 
　 　 0.80 0.92 0.84 0.80 0.78 0.77 0.76 0.75 0.75 0.74 0.74 　 0.93 0.85 0.83 0.82 0.82 0.82 0.82 0.83 0.84 0.85 
　 　 0.85 0.87 0.79 0.76 0.74 0.72 0.71 0.71 0.70 0.70 0.69 　 0.87 0.81 0.78 0.78 0.78 0.78 0.79 0.80 0.81 0.82 
　 　 0.90 0.82 0.75 0.71 0.69 0.68 0.67 0.67 0.66 0.66 0.65 　 0.83 0.76 0.74 0.74 0.74 0.75 0.75 0.76 0.78 0.79 
　 0.55 0.70 　 　 0.99 0.97 0.96 0.95 0.94 0.93 0.93 0.93 　 　 　 1.00 0.98 0.97 0.96 0.96 0.96 0.96 0.96 
　 　 0.75 　 0.97 0.93 0.90 0.89 0.88 0.87 0.87 0.87 0.86 　 　 0.97 0.94 0.92 0.92 0.91 0.91 0.92 0.92 0.93 
　 　 0.80 0.99 0.90 0.87 0.85 0.83 0.82 0.82 0.81 0.81 0.81 　 0.99 0.91 0.89 0.87 0.87 0.87 0.87 0.88 0.89 0.89 
　 　 0.85 0.93 0.85 0.82 0.80 0.78 0.77 0.77 0.76 0.76 0.76 　 0.93 0.86 0.84 0.83 0.83 0.83 0.84 0.84 0.85 0.86 
　 　 0.90 0.88 0.80 0.77 0.75 0.74 0.73 0.72 0.72 0.71 0.71 　 0.88 0.82 0.80 0.79 0.79 0.79 0.80 0.81 0.82 0.83 
　 0.60 0.75 　 　 1.00 0.97 0.96 0.95 0.94 0.94 0.94 0.94 　 　 　 1.00 0.98 0.97 0.96 0.96 0.96 0.96 0.97 
　 　 0.80 　 0.97 0.93 0.91 0.90 0.89 0.88 0.88 0.87 0.87 　 　 0.97 0.94 0.93 0.92 0.92 0.92 0.92 0.93 0.93 
　 　 0.85 0.99 0.91 0.88 0.86 0.84 0.83 0.83 0.82 0.82 0.82 　 0.99 0.92 0.89 0.88 0.88 0.88 0.88 0.89 0.89 0.90 
　 　 0.90 0.93 0.86 0.83 0.81 0.80 0.79 0.78 0.78 0.77 0.77 　 0.94 0.87 0.85 0.84 0.84 0.84 0.85 0.85 0.86 0.87 
　 0.65 0.80 　 　 1.00 0.98 0.96 0.95 0.95 0.94 0.94 0.94 　 　 　 1.00 0.98 0.97 0.97 0.97 0.97 0.97 0.97 
　 　 0.85 　 0.97 0.94 0.92 0.90 0.90 0.89 0.89 0.88 0.88 　 　 0.97 0.94 0.93 0.93 0.92 0.93 0.93 0.93 0.94 
　 　 0.90 0.99 0.91 0.88 0.86 0.85 0.84 0.84 0.83 0.83 0.83 　 0.99 0.92 0.90 0.89 0.89 0.89 0.89 0.89 0.90 0.91 
　 0.70 0.85 　 　 1.00 0.98 0.96 0.96 0.95 0.95 0.94 0.94 　 　 　 1.00 0.98 0.97 0.97 0.97 0.97 0.97 0.97 
　 　 0.90 　 0.97 0.94 0.92 0.91 0.90 0.90 0.89 0.89 0.89 　 　 0.97 0.95 0.94 0.93 0.93 0.93 0.93 0.94 0.94 
　 0.75 0.90 　 　 1.00 0.98 0.97 0.96 0.95 0.95 0.95 0.95 　 　 　 1.00 0.98 0.98 0.97 0.97 0.97 0.97 0.97 
0.25 0.40 0.50 　 　 　 　 0.99 0.98 0.97 0.97 0.97 0.96 　 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 
　 　 0.55 　 0.98 0.94 0.91 0.90 0.89 0.88 0.88 0.87 0.87 　 　 0.98 0.95 0.93 0.92 0.92 0.92 0.92 0.93 0.93 
　 　 0.60 0.99 0.90 0.86 0.84 0.82 0.81 0.80 0.80 0.80 0.79 　 0.99 0.91 0.88 0.86 0.86 0.86 0.86 0.87 0.88 0.88 
　 　 0.65 0.91 0.83 0.79 0.77 0.76 0.75 0.74 0.73 0.73 0.73 　 0.91 0.84 0.82 0.81 0.81 0.81 0.81 0.82 0.83 0.84 
　 　 0.70 0.84 0.77 0.73 0.71 0.70 0.69 0.69 0.68 0.68 0.67 　 0.85 0.79 0.76 0.76 0.76 0.76 0.77 0.78 0.79 0.81 
　 　 0.75 0.79 0.71 0.68 0.67 0.65 0.64 0.64 0.63 0.63 0.63 　 0.80 0.74 0.72 0.71 0.72 0.72 0.73 0.74 0.76 0.77 
- 84 -

or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
　 　 0.80 0.74 0.67 0.64 0.62 0.61 0.60 0.60 0.59 0.59 0.59 　 0.75 0.69 0.68 0.67 0.68 0.68 0.70 0.71 0.72 0.74 
　 　 0.85 0.69 0.63 0.60 0.59 0.57 0.57 0.56 0.56 0.55 0.55 　 0.70 0.65 0.64 0.64 0.64 0.65 0.66 0.68 0.69 0.71 
　 　 0.90 0.65 0.59 0.57 0.55 0.54 0.53 0.53 0.53 0.52 0.52 　 0.67 0.62 0.61 0.61 0.61 0.62 0.63 0.65 0.66 0.68 
　 0.45 0.55 　 　 　 　 0.99 0.98 0.98 0.97 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.98 0.98 0.98 
　 　 0.60 　 0.98 0.94 0.92 0.91 0.90 0.89 0.89 0.88 0.88 　 　 0.98 0.95 0.94 0.93 0.93 0.93 0.93 0.93 0.94 
　 　 0.65 0.99 0.91 0.87 0.85 0.84 0.83 0.82 0.82 0.81 0.81 　 0.99 0.91 0.89 0.88 0.87 0.87 0.88 0.88 0.89 0.90 
　 　 0.70 0.92 0.84 0.81 0.79 0.77 0.77 0.76 0.75 0.75 0.75 　 0.92 0.85 0.83 0.82 0.82 0.82 0.83 0.84 0.85 0.86 
　 　 0.75 0.85 0.78 0.75 0.73 0.72 0.71 0.71 0.70 0.70 0.70 　 0.86 0.80 0.78 0.77 0.78 0.78 0.79 0.80 0.81 0.82 
　 　 0.80 0.80 0.73 0.70 0.69 0.68 0.67 0.66 0.66 0.65 0.65 　 0.81 0.75 0.74 0.73 0.74 0.74 0.75 0.76 0.77 0.79 
　 　 0.85 0.75 0.69 0.66 0.65 0.63 0.63 0.62 0.62 0.61 0.61 　 0.76 0.71 0.70 0.69 0.70 0.71 0.72 0.73 0.74 0.76 
　 　 0.90 0.71 0.65 0.62 0.61 0.60 0.59 0.59 0.58 0.58 0.58 　 0.72 0.67 0.66 0.66 0.67 0.67 0.69 0.70 0.71 0.73 
　 0.50 0.60 　 　 　 　 0.99 0.99 0.98 0.97 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.98 0.98 0.99 
　 　 0.65 　 0.98 0.95 0.93 0.92 0.91 0.90 0.90 0.89 0.89 　 　 0.99 0.96 0.94 0.94 0.93 0.93 0.94 0.94 0.94 
　 　 0.70 0.99 0.91 0.88 0.86 0.85 0.84 0.83 0.83 0.83 0.82 　 0.99 0.92 0.90 0.89 0.88 0.88 0.89 0.89 0.90 0.90 
　 　 0.75 0.92 0.85 0.82 0.80 0.79 0.78 0.78 0.77 0.77 0.77 　 0.93 0.86 0.84 0.83 0.83 0.84 0.84 0.85 0.86 0.87 
　 　 0.80 0.86 0.80 0.77 0.75 0.74 0.73 0.73 0.72 0.72 0.72 　 0.87 0.81 0.80 0.79 0.79 0.80 0.80 0.81 0.82 0.84 
　 　 0.85 0.81 0.75 0.72 0.71 0.69 0.69 0.68 0.68 0.67 0.67 　 0.82 0.77 0.75 0.75 0.75 0.76 0.77 0.78 0.79 0.80 
　 　 0.90 0.77 0.71 0.68 0.67 0.66 0.65 0.64 0.64 0.64 0.63 　 0.78 0.73 0.72 0.71 0.72 0.72 0.74 0.75 0.76 0.78 
　 0.55 0.65 　 　 　 　 0.99 0.99 0.98 0.98 0.97 0.97 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.70 　 0.98 0.95 0.93 0.92 0.91 0.91 0.90 0.90 0.90 　 　 0.99 0.96 0.95 0.94 0.94 0.94 0.94 0.94 0.95 
　 　 0.75 0.99 0.92 0.89 0.87 0.86 0.85 0.84 0.84 0.84 0.84 　 0.99 0.93 0.90 0.89 0.89 0.89 0.89 0.90 0.90 0.91 
　 　 0.80 0.93 0.86 0.83 0.81 0.80 0.80 0.79 0.79 0.78 0.78 　 0.93 0.87 0.85 0.85 0.85 0.85 0.85 0.86 0.87 0.88 
　 　 0.85 0.87 0.81 0.78 0.77 0.75 0.75 0.74 0.74 0.74 0.73 　 0.88 0.82 0.81 0.80 0.80 0.81 0.82 0.83 0.84 0.85 
　 　 0.90 0.82 0.76 0.74 0.72 0.71 0.71 0.70 0.70 0.69 0.69 　 0.83 0.78 0.77 0.76 0.77 0.77 0.78 0.79 0.80 0.82 
　 0.60 0.70 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.75 　 0.99 0.96 0.94 0.93 0.92 0.91 0.91 0.91 0.91 　 　 0.99 0.96 0.95 0.94 0.94 0.94 0.94 0.95 0.95 
　 　 0.80 0.99 0.92 0.89 0.88 0.87 0.86 0.85 0.85 0.85 0.85 　 0.99 0.93 0.91 0.90 0.90 0.90 0.90 0.91 0.91 0.92 
　 　 0.85 0.93 0.87 0.84 0.83 0.82 0.81 0.80 0.80 0.80 0.80 　 0.93 0.88 0.86 0.86 0.85 0.86 0.86 0.87 0.88 0.89 
　 　 0.90 0.88 0.82 0.79 0.78 0.77 0.76 0.76 0.75 0.75 0.75 　 0.88 0.83 0.82 0.81 0.82 0.82 0.83 0.84 0.85 0.86 
　 0.65 0.75 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.80 　 0.99 0.96 0.94 0.93 0.92 0.92 0.92 0.91 0.91 　 　 0.99 0.96 0.95 0.95 0.95 0.95 0.95 0.95 0.96 
　 　 0.85 0.99 0.93 0.90 0.89 0.88 0.87 0.86 0.86 0.86 0.86 　 0.99 0.93 0.91 0.91 0.90 0.90 0.91 0.91 0.92 0.92 
　 　 0.90 0.93 0.88 0.85 0.84 0.83 0.82 0.81 0.81 0.81 0.81 　 0.94 0.89 0.87 0.86 0.86 0.87 0.87 0.88 0.89 0.89 
　 0.70 0.80 　 　 　 　 1.00 0.99 0.98 0.98 0.98 0.98 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.85 　 0.99 0.96 0.95 0.94 0.93 0.92 0.92 0.92 0.92 　 　 0.99 0.97 0.96 0.95 0.95 0.95 0.95 0.95 0.96 
　 　 0.90 0.99 0.93 0.91 0.89 0.88 0.88 0.87 0.87 0.87 0.87 　 0.99 0.94 0.92 0.91 0.91 0.91 0.91 0.92 0.92 0.93 
- 85 -

or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
　 0.75 0.85 　 　 　 　 1.00 0.99 0.99 0.98 0.98 0.98 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
　 　 0.90 　 0.99 0.96 0.95 0.94 0.93 0.93 0.93 0.92 0.92 　 　 0.99 0.97 0.96 0.95 0.95 0.95 0.95 0.96 0.96 
　 0.80 0.90 　 　 　 　 1.00 0.99 0.99 0.98 0.98 0.98 　 　 　 　 　 1.00 0.99 0.99 0.99 0.99 0.99 
0.30 0.40 0.50 　 　 0.98 0.96 0.95 0.94 0.93 0.93 0.93 0.93 　 　 　 0.98 0.97 0.96 0.96 0.96 0.96 0.96 0.96 
　 　 0.55 1.00 0.92 0.89 0.87 0.86 0.85 0.84 0.84 0.84 0.84 　 1.00 0.93 0.90 0.89 0.89 0.89 0.89 0.90 0.90 0.91 
　 　 0.60 0.91 0.84 0.81 0.80 0.79 0.78 0.77 0.77 0.77 0.76 　 0.92 0.86 0.84 0.83 0.83 0.83 0.84 0.85 0.86 0.87 
　 　 0.65 0.84 0.78 0.75 0.73 0.72 0.72 0.71 0.71 0.70 0.70 　 0.85 0.80 0.78 0.78 0.78 0.78 0.79 0.80 0.81 0.83 
　 　 0.70 0.78 0.72 0.70 0.68 0.67 0.66 0.66 0.66 0.65 0.65 　 0.79 0.74 0.73 0.73 0.73 0.74 0.75 0.76 0.77 0.79 
　 　 0.75 0.73 0.67 0.65 0.64 0.63 0.62 0.61 0.61 0.61 0.61 　 0.74 0.70 0.69 0.69 0.69 0.70 0.71 0.72 0.74 0.75 
　 　 0.80 0.68 0.63 0.61 0.60 0.59 0.58 0.57 0.57 0.57 0.57 　 0.69 0.66 0.65 0.65 0.65 0.66 0.68 0.69 0.71 0.72 
　 　 0.85 0.64 0.59 0.57 0.56 0.55 0.55 0.54 0.54 0.53 0.53 　 0.65 0.62 0.61 0.61 0.62 0.63 0.64 0.66 0.68 0.69 
　 　 0.90 0.61 0.56 0.54 0.53 0.52 0.51 0.51 0.51 0.50 0.50 　 0.62 0.59 0.58 0.58 0.59 0.60 0.62 0.63 0.65 0.67 
　 0.45 0.55 　 　 0.98 0.96 0.95 0.95 0.94 0.94 0.93 0.93 　 　 　 0.99 0.97 0.96 0.96 0.96 0.96 0.96 0.97 
　 　 0.60 1.00 0.93 0.90 0.88 0.87 0.86 0.86 0.85 0.85 0.85 　 1.00 0.94 0.91 0.90 0.90 0.90 0.90 0.91 0.91 0.92 
　 　 0.65 0.92 0.86 0.83 0.81 0.80 0.80 0.79 0.79 0.78 0.78 　 0.92 0.87 0.85 0.84 0.84 0.85 0.85 0.86 0.87 0.88 
　 　 0.70 0.85 0.79 0.77 0.75 0.74 0.74 0.73 0.73 0.73 0.72 　 0.86 0.81 0.80 0.79 0.80 0.80 0.81 0.82 0.83 0.84 
　 　 0.75 0.80 0.74 0.72 0.70 0.69 0.69 0.68 0.68 0.68 0.67 　 0.80 0.76 0.75 0.75 0.75 0.76 0.77 0.78 0.79 0.81 
　 　 0.80 0.75 0.69 0.67 0.66 0.65 0.64 0.64 0.64 0.63 0.63 　 0.76 0.72 0.71 0.71 0.71 0.72 0.73 0.74 0.76 0.77 
　 　 0.85 0.70 0.65 0.63 0.62 0.61 0.60 0.60 0.60 0.59 0.59 　 0.71 0.68 0.67 0.67 0.68 0.69 0.70 0.71 0.73 0.74 
　 　 0.90 0.66 0.62 0.60 0.58 0.58 0.57 0.57 0.56 0.56 0.56 　 0.67 0.64 0.63 0.64 0.64 0.66 0.67 0.68 0.70 0.72 
　 0.50 0.60 　 　 0.98 0.97 0.96 0.95 0.94 0.94 0.94 0.94 　 　 　 0.99 0.97 0.97 0.96 0.96 0.96 0.97 0.97 
　 　 0.65 1.00 0.93 0.91 0.89 0.88 0.87 0.87 0.87 0.86 0.86 　 1.00 0.94 0.92 0.91 0.91 0.91 0.91 0.92 0.92 0.93 
　 　 0.70 0.93 0.87 0.84 0.83 0.82 0.81 0.81 0.80 0.80 0.80 　 0.93 0.88 0.86 0.86 0.86 0.86 0.86 0.87 0.88 0.89 
　 　 0.75 0.86 0.81 0.78 0.77 0.76 0.76 0.75 0.75 0.74 0.74 　 0.87 0.82 0.81 0.81 0.81 0.82 0.82 0.83 0.84 0.85 
　 　 0.80 0.81 0.76 0.73 0.72 0.71 0.71 0.70 0.70 0.70 0.70 　 0.82 0.78 0.77 0.76 0.77 0.78 0.78 0.80 0.81 0.82 
　 　 0.85 0.76 0.71 0.69 0.68 0.67 0.66 0.66 0.66 0.65 0.65 　 0.77 0.73 0.72 0.73 0.73 0.74 0.75 0.76 0.78 0.79 
　 　 0.90 0.72 0.67 0.65 0.64 0.63 0.63 0.62 0.62 0.62 0.62 　 0.73 0.70 0.69 0.69 0.70 0.71 0.72 0.73 0.75 0.76 
　 0.55 0.65 　 　 0.99 0.97 0.96 0.95 0.95 0.95 0.94 0.94 　 　 　 0.99 0.98 0.97 0.97 0.97 0.97 0.97 0.97 
　 　 0.70 1.00 0.94 0.91 0.90 0.89 0.88 0.88 0.88 0.87 0.87 　 1.00 0.95 0.93 0.92 0.92 0.92 0.92 0.92 0.93 0.93 
　 　 0.75 0.93 0.88 0.85 0.84 0.83 0.82 0.82 0.82 0.81 0.81 　 0.93 0.89 0.87 0.87 0.87 0.87 0.87 0.88 0.89 0.90 
　 　 0.80 0.87 0.82 0.80 0.79 0.78 0.77 0.77 0.76 0.76 0.76 　 0.88 0.84 0.82 0.82 0.82 0.83 0.84 0.84 0.85 0.86 
　 　 0.85 0.82 0.77 0.75 0.74 0.73 0.72 0.72 0.72 0.72 0.71 　 0.83 0.79 0.78 0.78 0.78 0.79 0.80 0.81 0.82 0.83 
　 　 0.90 0.77 0.73 0.71 0.70 0.69 0.68 0.68 0.68 0.67 0.67 　 0.78 0.75 0.74 0.74 0.75 0.76 0.77 0.78 0.79 0.80 
　 0.60 0.70 　 　 0.99 0.97 0.96 0.96 0.95 0.95 0.95 0.95 　 　 　 0.99 0.98 0.97 0.97 0.97 0.97 0.97 0.97 
　 　 0.75 1.00 0.94 0.92 0.91 0.90 0.89 0.89 0.88 0.88 0.88 　 1.00 0.95 0.93 0.92 0.92 0.92 0.92 0.93 0.93 0.94 
　 　 0.80 0.94 0.88 0.86 0.85 0.84 0.83 0.83 0.83 0.83 0.82 　 0.94 0.89 0.88 0.88 0.88 0.88 0.88 0.89 0.90 0.90 
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
or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
　 　 0.85 0.88 0.83 0.81 0.80 0.79 0.78 0.78 0.78 0.78 0.77 　 0.89 0.85 0.83 0.83 0.83 0.84 0.85 0.85 0.86 0.87 
　 　 0.90 0.83 0.78 0.76 0.75 0.75 0.74 0.74 0.73 0.73 0.73 　 0.84 0.80 0.79 0.79 0.80 0.80 0.81 0.82 0.83 0.84 
　 0.65 0.75 　 　 0.99 0.97 0.97 0.96 0.96 0.95 0.95 0.95 　 　 　 0.99 0.98 0.97 0.97 0.97 0.97 0.97 0.98 
　 　 0.80 1.00 0.95 0.93 0.91 0.90 0.90 0.90 0.89 0.89 0.89 　 1.00 0.95 0.94 0.93 0.93 0.93 0.93 0.93 0.94 0.94 
　 　 0.85 0.94 0.89 0.87 0.86 0.85 0.84 0.84 0.84 0.84 0.84 　 0.94 0.90 0.89 0.88 0.88 0.89 0.89 0.90 0.90 0.91 
　 　 0.90 0.89 0.84 0.82 0.81 0.80 0.80 0.79 0.79 0.79 0.79 　 0.89 0.85 0.84 0.84 0.84 0.85 0.86 0.86 0.87 0.88 
　 0.70 0.80 　 　 0.99 0.98 0.97 0.96 0.96 0.96 0.96 0.95 　 　 　 0.99 0.98 0.98 0.97 0.97 0.97 0.98 0.98 
　 　 0.85 1.00 0.95 0.93 0.92 0.91 0.91 0.90 0.90 0.90 0.90 　 1.00 0.96 0.94 0.93 0.93 0.93 0.93 0.94 0.94 0.95 
　 　 0.90 0.94 0.90 0.88 0.87 0.86 0.85 0.85 0.85 0.85 0.85 　 0.95 0.91 0.89 0.89 0.89 0.89 0.90 0.90 0.91 0.92 
　 0.75 0.85 　 　 0.99 0.98 0.97 0.97 0.96 0.96 0.96 0.96 　 　 　 0.99 0.98 0.98 0.98 0.98 0.98 0.98 0.98 
　 　 0.90 1.00 0.95 0.93 0.92 0.92 0.91 0.91 0.90 0.90 0.90 　 1.00 0.96 0.94 0.94 0.94 0.94 0.94 0.94 0.94 0.95 
　 0.80 0.90 　 　 0.99 0.98 0.97 0.97 0.96 0.96 0.96 0.96 　 　 　 0.99 0.98 0.98 0.98 0.98 0.98 0.98 0.98 
0.35 0.40 0.45 　 　 　 　 　 　 1.00 1.00 0.99 0.99 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.50 　 0.96 0.93 0.92 0.91 0.90 0.90 0.89 0.89 0.89 　 　 0.96 0.94 0.93 0.93 0.93 0.93 0.93 0.94 0.94 
　 　 0.55 0.92 0.87 0.85 0.83 0.82 0.82 0.81 0.81 0.81 0.81 　 0.93 0.88 0.87 0.86 0.86 0.86 0.87 0.88 0.88 0.89 
　 　 0.60 0.85 0.80 0.77 0.76 0.75 0.75 0.74 0.74 0.74 0.74 　 0.85 0.81 0.80 0.80 0.80 0.81 0.82 0.83 0.84 0.85 
　 　 0.65 0.78 0.73 0.71 0.70 0.69 0.69 0.68 0.68 0.68 0.68 　 0.79 0.75 0.75 0.75 0.75 0.76 0.77 0.78 0.79 0.81 
　 　 0.70 0.72 0.68 0.66 0.65 0.64 0.64 0.64 0.63 0.63 0.63 　 0.73 0.70 0.70 0.70 0.71 0.72 0.73 0.74 0.76 0.77 
　 　 0.75 0.68 0.64 0.62 0.61 0.60 0.60 0.59 0.59 0.59 0.59 　 0.69 0.66 0.66 0.66 0.67 0.68 0.69 0.71 0.72 0.74 
　 　 0.80 0.63 0.60 0.58 0.57 0.56 0.56 0.55 0.55 0.55 0.55 　 0.65 0.62 0.62 0.62 0.63 0.64 0.66 0.67 0.69 0.71 
　 　 0.85 0.60 0.56 0.54 0.54 0.53 0.52 0.52 0.52 0.52 0.52 　 0.61 0.59 0.58 0.59 0.60 0.61 0.63 0.64 0.66 0.68 
　 　 0.90 0.56 0.53 0.51 0.51 0.50 　 　 　 　 　 　 0.58 0.56 0.55 0.56 0.57 0.58 0.60 0.62 0.63 0.65 
　 0.45 0.50 　 　 　 　 　 　 1.00 1.00 1.00 0.99 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.55 　 0.96 0.94 0.92 0.92 0.91 0.91 0.90 0.90 0.90 　 　 0.96 0.95 0.94 0.94 0.94 0.94 0.94 0.94 0.95 
　 　 0.60 0.93 0.88 0.86 0.85 0.84 0.83 0.83 0.83 0.82 0.82 　 0.93 0.89 0.88 0.87 0.87 0.88 0.88 0.89 0.90 0.90 
　 　 0.65 0.86 0.81 0.79 0.78 0.77 0.77 0.76 0.76 0.76 0.76 　 0.86 0.83 0.82 0.82 0.82 0.83 0.83 0.84 0.85 0.86 
　 　 0.70 0.80 0.75 0.73 0.72 0.72 0.71 0.71 0.71 0.70 0.70 　 0.80 0.77 0.77 0.77 0.77 0.78 0.79 0.80 0.81 0.83 
　 　 0.75 0.74 0.70 0.69 0.67 0.67 0.66 0.66 0.66 0.66 0.65 　 0.75 0.72 0.72 0.72 0.73 0.74 0.75 0.76 0.78 0.79 
　 　 0.80 0.70 0.66 0.64 0.63 0.63 0.62 0.62 0.62 0.61 0.61 　 0.71 0.68 0.68 0.68 0.69 0.70 0.71 0.73 0.74 0.76 
　 　 0.85 0.66 0.62 0.60 0.59 0.59 0.58 0.58 0.58 0.58 0.58 　 0.67 0.64 0.64 0.65 0.66 0.67 0.68 0.70 0.71 0.73 
　 　 0.90 0.62 0.59 0.57 0.56 0.56 0.55 0.55 0.55 0.54 0.54 　 0.63 0.61 0.61 0.62 0.63 0.64 0.65 0.67 0.68 0.70 
　 0.50 0.55 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.60 　 0.96 0.94 0.93 0.92 0.92 0.91 0.91 0.91 0.91 　 　 0.97 0.95 0.94 0.94 0.94 0.94 0.95 0.95 0.95 
　 　 0.65 0.94 0.89 0.87 0.86 0.85 0.85 0.84 0.84 0.84 0.84 　 0.94 0.90 0.89 0.88 0.88 0.89 0.89 0.90 0.90 0.91 
　 　 0.70 0.87 0.83 0.81 0.80 0.79 0.78 0.78 0.78 0.78 0.78 　 0.87 0.84 0.83 0.83 0.83 0.84 0.85 0.85 0.86 0.87 
　 　 0.75 0.81 0.77 0.75 0.74 0.74 0.73 0.73 0.73 0.72 0.72 　 0.82 0.79 0.78 0.78 0.79 0.80 0.80 0.82 0.83 0.84 
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
or


∆

∆
 : Similarity criteria I 　  : Similarity criteria II
0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 　 0.05 0.10 0.15 0.20 0.25 0.30 0.35 0.40 0.45 0.50 
　 　 0.80 0.76 0.72 0.71 0.70 0.69 0.68 0.68 0.68 0.68 0.68 　 0.77 0.74 0.74 0.74 0.75 0.76 0.77 0.78 0.79 0.81 
　 　 0.85 0.71 0.68 0.66 0.65 0.65 0.64 0.64 0.64 0.64 0.64 　 0.72 0.70 0.70 0.70 0.71 0.72 0.73 0.75 0.76 0.78 
　 　 0.90 0.67 0.64 0.63 0.62 0.61 0.61 0.60 0.60 0.60 0.60 　 0.69 0.66 0.66 0.67 0.68 0.69 0.70 0.72 0.73 0.75 
　 0.55 0.60 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.65 　 0.97 0.95 0.94 0.93 0.92 0.92 0.92 0.92 0.92 　 　 0.97 0.96 0.95 0.95 0.95 0.95 0.95 0.95 0.96 
　 　 0.70 0.94 0.90 0.88 0.87 0.86 0.86 0.85 0.85 0.85 0.85 　 0.94 0.91 0.90 0.89 0.89 0.90 0.90 0.91 0.91 0.92 
　 　 0.75 0.88 0.84 0.82 0.81 0.80 0.80 0.80 0.79 0.79 0.79 　 0.88 0.85 0.84 0.84 0.85 0.85 0.86 0.87 0.87 0.88 
　 　 0.80 0.82 0.78 0.77 0.76 0.75 0.75 0.75 0.74 0.74 0.74 　 0.83 0.80 0.80 0.80 0.80 0.81 0.82 0.83 0.84 0.85 
　 　 0.85 0.77 0.74 0.72 0.71 0.71 0.70 0.70 0.70 0.70 0.70 　 0.78 0.76 0.75 0.76 0.76 0.77 0.78 0.79 0.81 0.82 
　 　 0.90 0.73 0.70 0.68 0.67 0.67 0.66 0.66 0.66 0.66 0.66 　 0.74 0.72 0.72 0.72 0.73 0.74 0.75 0.76 0.78 0.79 
　 0.60 0.65 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.70 　 0.97 0.95 0.94 0.93 0.93 0.93 0.92 0.92 0.92 　 　 0.97 0.96 0.95 0.95 0.95 0.95 0.95 0.96 0.96 
　 　 0.75 0.94 0.90 0.89 0.88 0.87 0.87 0.86 0.86 0.86 0.86 　 0.95 0.91 0.90 0.90 0.90 0.90 0.91 0.91 0.92 0.92 
　 　 0.80 0.89 0.85 0.83 0.82 0.82 0.81 0.81 0.81 0.81 0.80 　 0.89 0.86 0.85 0.85 0.86 0.86 0.87 0.87 0.88 0.89 
　 　 0.85 0.83 0.80 0.78 0.77 0.77 0.76 0.76 0.76 0.76 0.76 　 0.84 0.81 0.81 0.81 0.81 0.82 0.83 0.84 0.85 0.86 
　 　 0.90 0.79 0.75 0.74 0.73 0.72 0.72 0.72 0.72 0.71 0.71 　 0.79 0.77 0.77 0.77 0.78 0.79 0.80 0.81 0.82 0.83 
　 0.65 0.70 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.75 　 0.97 0.95 0.95 0.94 0.93 0.93 0.93 0.93 0.93 　 　 0.97 0.96 0.96 0.95 0.95 0.95 0.96 0.96 0.96 
　 　 0.80 0.95 0.91 0.89 0.89 0.88 0.88 0.87 0.87 0.87 0.87 　 0.95 0.92 0.91 0.91 0.91 0.91 0.91 0.92 0.92 0.93 
　 　 0.85 0.89 0.86 0.84 0.83 0.83 0.82 0.82 0.82 0.82 0.82 　 0.90 0.87 0.86 0.86 0.86 0.87 0.88 0.88 0.89 0.90 
　 　 0.90 0.84 0.81 0.79 0.79 0.78 0.78 0.77 0.77 0.77 0.77 　 0.85 0.82 0.82 0.82 0.83 0.83 0.84 0.85 0.86 0.87 
　 0.70 0.75 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.80 　 0.97 0.96 0.95 0.94 0.94 0.94 0.93 0.93 0.93 　 　 0.98 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.97 
　 　 0.85 0.95 0.92 0.90 0.89 0.89 0.88 0.88 0.88 0.88 0.88 　 0.95 0.92 0.91 0.91 0.91 0.92 0.92 0.92 0.93 0.93 
　 　 0.90 0.90 0.86 0.85 0.84 0.84 0.83 0.83 0.83 0.83 0.83 　 0.90 0.88 0.87 0.87 0.87 0.88 0.88 0.89 0.90 0.91 
　 0.75 0.80 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.85 　 0.98 0.96 0.95 0.95 0.94 0.94 0.94 0.94 0.94 　 　 0.98 0.97 0.96 0.96 0.96 0.96 0.96 0.96 0.97 
　 　 0.90 0.95 0.92 0.91 0.90 0.89 0.89 0.89 0.89 0.88 0.88 　 0.96 0.93 0.92 0.92 0.92 0.92 0.92 0.93 0.93 0.94 
　 0.80 0.85 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
　 　 0.90 　 0.98 0.96 0.95 0.95 0.95 0.94 0.94 0.94 0.94 　 　 0.98 0.97 0.96 0.96 0.96 0.96 0.96 0.97 0.97 
　 0.85 0.90 　 　 　 　 　 　 1.00 1.00 1.00 1.00 　 　 　 　 　 　 　 1.00 1.00 1.00 1.00 
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

or

　
∆
　
∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
0.8 0.1 0.2 0.40 　 　 　 　 0.2700 0.1638 　 　 　 　 　 　 0.2464 
　 　 　 0.45 　 　 0.3194 0.2042 0.1352 0.0870 　 　 　 　 　 0.1636 0.0960 
　 　 　 0.50 　 0.3542 0.1792 0.1224 0.0832 0.0544 　 　 　 0.2372 0.1406 0.0904 0.0572 
　 　 0.4 0.65 　 　 　 　 0.2700 0.1638 　 　 　 　 　 　 　
　 　 　 0.70 　 　 0.3194 0.2042 0.1352 0.0870 　 　 　 　 　 0.2068 0.1034 
　 　 　 0.75 　 0.3536 0.1792 0.1224 0.0832 0.0544 　 　 　 　 0.1564 0.0950 0.0588 
　 　 　 0.80 　 0.2136 0.1186 0.0826 0.0568 0.0374 　 　 　 0.1442 0.0924 0.0610 0.0390 
　 　 　 0.85 　 0.1486 0.0850 0.0596 0.0412 0.0274 　 　 0.1924 0.0946 0.0638 0.0432 0.0280 
　 　 　 0.90 0.5272 0.1106 0.0642 0.0452 0.0314 0.0208 　 　 0.1270 0.0688 0.0474 0.0324 0.0212 
　 0.15 0.2 0.35 　 　 　 　 　 0.2642 　 　 　 　 　 　 　
　 　 　 0.40 　 　 0.4186 0.2476 0.1608 0.1026 　 　 　 　 　 0.2354 0.1196 
　 　 　 0.45 　 0.3714 0.1844 0.1258 0.0854 0.0558 　 　 　 0.2758 0.1490 0.0942 0.0592 
　 　 　 0.50 　 0.1992 0.1114 0.0776 0.0534 0.0352 　 　 0.2960 0.1258 0.0838 0.0562 0.0364 
　 　 0.4 0.60   　 　 　 　 　 0.2642  　 　 　 　 　 　 　
　 　 　 0.65 　 　 0.4178 0.2476 0.1608 0.1026 　 　 　 　 　 　 0.1410 
　 　 　 0.70 　 0.3688 0.1844 0.1258 0.0854 0.0558 　 　 　 　 0.1770 0.1010 0.0614 
　 　 　 0.75 　 0.1992 0.1114 0.0776 0.0534 0.0352 　 　 　 0.1372 0.0876 0.0576 0.0370 
　 　 　 0.80 　 0.1308 0.0754 0.0530 0.0368 0.0244 　 　 0.1652 0.0834 0.0566 0.0384 0.0250 
　 　 　 0.85 0.3566 0.0936 0.0546 0.0386 0.0268 0.0178 　 　 0.1056 0.0580 0.0402 0.0276 0.0182 
　 　 　 0.90 0.2426 0.0704 0.0414 0.0294 0.0204 0.0136 　 　 0.0760 0.0432 0.0302 0.0208 0.0138 
　 0.2 0.2 0.35 　 　 　 0.4886 0.2598 0.1586 　 　 　 　 　 　 　
　 　 　 0.40 　 　 0.2234 0.1500 0.1012 0.0658 　 　 　 　 0.2048 0.1178 0.0716 
　 　 　 0.45 　 0.2066 0.1150 0.0800 0.0552 0.0364 　 　 　 0.1332 0.0876 0.0584 0.0376 
　 　 　 0.50 　 0.1234 0.0714 0.0502 0.0348 0.0230 　 　 0.1420 0.0764 0.0526 0.0358 0.0236 
　 　 0.4 0.60 　 　 　 0.4876 0.2598 0.1586 　 　 　 　 　 　 　
　 　 　 0.65 　 　 0.2234 0.1500 0.1012 0.0658 　 　 　 　 　 0.1380 0.0766 
Appendix E : Table A3.  to calculate the sample size in the region of interest
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

or

　
∆
　
∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
　 　 　 0.70 　 0.2062 0.1150 0.0800 0.0552 0.0364 　 　 　 0.1520 0.0934 0.0606 0.0384 
　 　 　 0.75 　 0.1234 0.0714 0.0502 0.0348 0.0230 　 　 0.1584 0.0794 0.0538 0.0364 0.0238 
　 　 　 0.80 0.3012 0.0832 0.0488 0.0346 0.0240 0.0160 　 　 0.0934 0.0518 0.0360 0.0248 0.0162 
　 　 　 0.85 0.2012 0.0602 0.0356 0.0252 0.0176 0.0118 　 　 0.0644 0.0370 0.0260 0.0180 0.0118 
　 　 　 0.90 0.1474 0.0456 0.0270 0.0192 0.0134 0.0090 　 0.1844 0.0478 0.0278 0.0196 0.0136 0.0090 
　 0.25 0.2 0.35 　 　 0.3782 0.2312 0.1512 0.0968 　 　 　 　 　 　 0.1186 
　 　 　 0.40 　 0.2442 0.1324 0.0918 0.0630 0.0414 　 　 　 0.1680 0.1048 0.0682 0.0434 
　 　 　 0.45 　 0.1234 0.0712 0.0502 0.0348 0.0230 　 　 0.1454 0.0770 0.0528 0.0360 0.0236 
　 　 　 0.50 0.3024 0.0762 0.0448 0.0318 0.0222 0.0148 　 　 0.0820 0.0466 0.0326 0.0226 0.0148 
　 　 0.4 0.60   　 　 0.3760  0.2312  0.1512  0.0968  　 　 　 　 　 　 　
　 　 　 0.65 　 0.2422 0.1324 0.0918 0.0630 0.0414 　 　 　 　 0.1186 0.0726 0.0450 
　 　 　 0.70 　 0.1234 0.0712 0.0502 0.0348 0.0230 　 　 0.1710 0.0812 0.0546 0.0368 0.0238 
　 　 　 0.75 0.2690 0.0762 0.0448 0.0318 0.0222 0.0148 　 　 0.0858 0.0476 0.0332 0.0228 0.0150 
　 　 　 0.80 0.1708 0.0522 0.0308 0.0220 0.0154 0.0102 　 0.2880 0.0556 0.0320 0.0224 0.0156 0.0104 
　 　 　 0.85 0.1206 0.0380 0.0226 0.0160 0.0112 0.0076 　 0.1438 0.0396 0.0230 0.0164 0.0114 0.0076 
　 　 　 0.90 0.0902 0.0288 0.0172 0.0124 0.0086 0.0058 　 0.1002 0.0298 0.0176 0.0124 0.0086 0.0058 
　 0.3 0.2 0.30 　 　 　 　 　 0.2676 　 　 　 　 　 　 　
　 　 　 0.35 　 0.4122 0.1868 0.1270 0.0864 0.0564 　 　 　 　 0.1808 0.1024 0.0620 
　 　 　 0.40 　 0.1328 0.0762 0.0536 0.0372 0.0246 　 　 0.1692 0.0844 0.0572 0.0388 0.0252 
　 　 　 0.45 0.3008 0.0712 0.0418 0.0298 0.0206 0.0138 　 　 0.0770 0.0436 0.0306 0.0212 0.0140 
　 　 　 0.50 0.1538 0.0448 0.0266 0.0190 0.0132 0.0088 　 0.1970 0.0466 0.0272 0.0192 0.0134 0.0088 
　 　 0.4 0.55 　 　 　 　 　 0.2676 　 　 　 　 　 　 　
　 　 　 0.60 　 0.3752 0.1866 0.1270 0.0864 0.0564 　 　 　 　 　 0.1300 0.0680 
　 　 　 0.65 　 0.1322 0.0762 0.0536 0.0372 0.0246 　 　 　 0.0920 0.0602 0.0400 0.0258 
　 　 　 0.70 0.2478 0.0712 0.0418 0.0298 0.0206 0.0138 　 　 0.0810 0.0448 0.0310 0.0214 0.0140 
　 　 　 0.75 0.1444 0.0448 0.0266 0.0190 0.0132 0.0088 　 0.2076 0.0476 0.0274 0.0194 0.0134 0.0090 
　 　 　 0.80 0.0966 0.0308 0.0184 0.0132 0.0092 0.0062 　 0.1114 0.0320 0.0188 0.0134 0.0092 0.0062 
　 　 　 0.85 0.0696 0.0226 0.0134 0.0096 0.0068 0.0046 　 0.0756 0.0230 0.0136 0.0098 0.0068 0.0046 
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

or

　
∆
　
∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
　 　 　 0.90 0.0528 0.0172 0.0104 0.0074 0.0052 0.0034 　 0.0556 0.0176 0.0104 0.0074 0.0052 0.0036 
　 0.35 0.2 0.30 　 　 　 0.3230 0.2008 0.1260 　 　 　 　 　 　 　
　 　 　 0.35 　 0.1658 0.0922 0.0646 0.0446 0.0294 　 　 　 0.1114 0.0724 0.0480 0.0308 
　 　 　 0.40 0.3372 0.0672 0.0396 0.0280 0.0196 0.0130 　 　 0.0734 0.0414 0.0290 0.0200 0.0132 
　 　 　 0.45 0.1316 0.0370 0.0220 0.0156 0.0110 0.0074 　 0.1674 0.0384 0.0224 0.0160 0.0110 0.0074 
　 　 　 0.50 0.0762 0.0234 0.0140 0.0100 0.0070 0.0048 　 0.0826 0.0240 0.0142 0.0102 0.0070 0.0048 
　 　 0.4 0.55 　 　 　 0.3220 0.2008 0.1260 　 　 　 　 　 　 　
　 　 　 0.60 　 0.1620 0.0922 0.0646 0.0446 0.0294 　 　 　 0.1534 0.0812 0.0510 0.0320 
　 　 　 0.65 0.2330 0.0670 0.0396 0.0280 0.0196 0.0130 　 　 0.0784 0.0428 0.0296 0.0202 0.0134 
　 　 　 0.70 0.1178 0.0370 0.0220 0.0156 0.0110 0.0074 　 0.1586 0.0392 0.0228 0.0160 0.0112 0.0074 
　 　 　 0.75 0.0728 0.0234 0.0140 0.0100 0.0070 0.0048 　 0.0814 0.0242 0.0142 0.0102 0.0072 0.0048 
　 　 　 0.80 0.0498 0.0162 0.0098 0.0070 0.0050 0.0034 　 0.0528 0.0166 0.0098 0.0070 0.0050 0.0034 
　 　 　 0.85 0.0362 0.0120 0.0072 0.0052 0.0036 0.0024 　 0.0376 0.0120 0.0072 0.0052 0.0036 0.0024 
　 　 　 0.90 0.0276 0.0092 0.0056 0.0040 0.0028 0.0020 　 0.0284 0.0092 0.0056 0.0040 0.0028 0.0020 
0.9 0.1 0.2 0.35 　 　 　 　 0.3344 0.1882 　 　 　 　 　 　 0.2294 
　 　 　 0.40 　 　 0.3552 0.2142 0.1388 0.0884 　 　 　 　 0.2604 0.1518 0.0928 
　 　 　 0.45 　 0.3670 0.1754 0.1186 0.0802 0.0522 　 　 　 0.1956 0.1260 0.0832 0.0534 
　 　 　 0.50 　 0.2022 0.1108 0.0768 0.0526 0.0346 　 　 0.2288 0.1166 0.0792 0.0538 0.0350 
　 　 0.4 0.55 　 　 　 　 　 0.3212 　 　 　 　 　 　 　
　 　 　 0.60 　 　 　 0.3142 0.1912 0.1186 　 　 　 　 　 0.2932 0.1360 
　 　 　 0.65 　 　 0.2276 0.1500 0.1002 0.0648 　 　 　 　 0.1752 0.1090 0.0680 
　 　 　 0.70 　 0.2522 0.1338 0.0920 0.0628 0.0410 　 　 　 0.1488 0.0980 0.0652 0.0422 
　 　 　 0.75 　 0.1600 0.0898 0.0626 0.0432 0.0284 　 　 0.1810 0.0948 0.0650 0.0442 0.0288 
　 　 　 0.80 　 0.1130 0.0650 0.0456 0.0316 0.0210 　 　 0.1206 0.0672 0.0466 0.0320 0.0212 
　 　 　 0.85 0.3304 0.0846 0.0492 0.0348 0.0242 0.0160 　 　 0.0882 0.0504 0.0354 0.0244 0.0162 
　 　 　 0.90 0.2330 0.0660 0.0388 0.0274 0.0190 0.0126 　 0.2836 0.0680 0.0394 0.0278 0.0192 0.0128 
　 0.15 0.2 0.35 　 　 　 0.3000 0.1846 0.1150 　 　 　 　 　 0.2228 0.1252 
　 　 　 0.40 　 0.4486 0.1922 0.1290 0.0868 0.0564 　 　 　 0.2242 0.1396 0.0910 0.0580 
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

or

　
∆
　
∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
　 　 　 0.45 　 0.1960 0.1078 0.0748 0.0512 0.0338 　 　 0.2240 0.1138 0.0774 0.0524 0.0342 
　 　 　 0.50 　 0.1224 0.0700 0.0492 0.0340 0.0224 　 　 0.1296 0.0722 0.0502 0.0344 0.0226 
　 　 0.4 0.55   　 　 　 　 0.3126  0.1792  　 　 　 　 　 　 　
　 　 　 0.60 　 　 0.2750 0.1764 0.1164 0.0748 　 　 　 　 0.2392 0.1330 0.0804 
　 　 　 0.65 　 0.2572 0.1358 0.0934 0.0636 0.0416 　 　 　 0.1548 0.1006 0.0668 0.0428 
　 　 　 0.70 　 0.1482 0.0838 0.0586 0.0404 0.0266 　 　 0.1682 0.0886 0.0608 0.0414 0.0270 
　 　 　 0.75 0.4704 0.0990 0.0572 0.0404 0.0280 0.0186 　 　 0.1054 0.0592 0.0412 0.0284 0.0188 
　 　 　 0.80 0.2582 0.0714 0.0418 0.0296 0.0206 0.0136 　 　 0.0740 0.0426 0.0300 0.0208 0.0138 
　 　 　 0.85 0.1828 0.0540 0.0318 0.0226 0.0158 0.0106 　 0.2076 0.0554 0.0324 0.0228 0.0158 0.0106 
　 　 　 0.90 0.1388 0.0424 0.0252 0.0178 0.0124 0.0084 　 0.1496 0.0432 0.0254 0.0180 0.0126 0.0084 
　 0.2 0.2 0.30 　 　 　 　 　 0.2292 　 　 　 　 　 　 　
　 　 　 0.35 　 　 0.2656 0.1712 0.1134 0.0728 　 　 　 　 0.2014 0.1232 0.0764 
　 　 　 0.40 　 0.2170 0.1176 0.0812 0.0556 0.0366 　 　 0.2666 0.1262 0.0850 0.0572 0.0372 
　 　 　 0.45 　 0.1196 0.0686 0.0482 0.0334 0.0220 　 　 0.1272 0.0708 0.0492 0.0338 0.0222 
　 　 　 0.50 0.3050 0.0774 0.0452 0.0320 0.0222 0.0148 　 　 0.0800 0.0460 0.0324 0.0224 0.0148 
　 　 0.4 0.55 　 　 　 0.2840 0.1766 0.1104 　 　 　 　 　 　 0.1322 
　 　 　 0.60 　 0.3182 0.1600 0.1088 0.0738 0.0482 　 　 　 0.2026 0.1226 0.0792 0.0502 
　 　 　 0.65 　 0.1514 0.0854 0.0596 0.0412 0.0272 　 　 0.1772 0.0914 0.0624 0.0424 0.0276 
　 　 　 0.70 0.3932 0.0928 0.0538 0.0380 0.0264 0.0174 　 　 0.0988 0.0556 0.0388 0.0268 0.0176 
　 　 　 0.75 0.2210 0.0632 0.0372 0.0264 0.0184 0.0122 　 0.2840 0.0654 0.0378 0.0266 0.0184 0.0122 
　 　 　 0.80 0.1520 0.0460 0.0272 0.0194 0.0136 0.0090 　 0.1682 0.0470 0.0276 0.0196 0.0136 0.0090 
　 　 　 0.85 0.1124 0.0350 0.0208 0.0148 0.0104 0.0070 　 0.1196 0.0356 0.0210 0.0150 0.0104 0.0070 
　 　 　 0.90 0.0870 0.0276 0.0164 0.0118 0.0082 0.0056 　 0.0908 0.0280 0.0166 0.0118 0.0082 0.0056 
　 0.25 0.2 0.30 　 　 　 0.3780 0.2170 0.1328 　 　 　 　 　 　 0.1566 
　 　 　 0.35 　 0.2974 0.1502 0.1026 0.0698 0.0456 　 　 　 0.1708 0.1104 0.0730 0.0468 
　 　 　 0.40 　 0.1266 0.0722 0.0506 0.0350 0.0232 　 　 0.1368 0.0750 0.0520 0.0356 0.0234 
　 　 　 0.45 0.2914 0.0734 0.0430 0.0304 0.0212 0.0140 　 　 0.0758 0.0438 0.0308 0.0212 0.0142 
　 　 　 0.50 0.1650 0.0484 0.0286 0.0202 0.0142 0.0094 　 0.1820 0.0492 0.0288 0.0204 0.0142 0.0094 
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

or

　
∆
　
∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
　 　 0.4 0.50   　 　 　 　 　 0.3196 　 　 　 　 　 　 　
　 　 　 0.55 　 　 0.2422 0.1584 0.1054 0.0680 　 　 　 　 0.2450 0.1246 0.0744 
　 　 　 0.60 　 0.1726 0.0964 0.0670 0.0462 0.0304 　 　 0.2298 0.1064 0.0714 0.0480 0.0312 
　 　 　 0.65 0.3868 0.0916 0.0532 0.0374 0.0260 0.0172 　 　 0.0986 0.0552 0.0384 0.0264 0.0174 
　 　 　 0.70 0.1972 0.0576 0.0338 0.0240 0.0168 0.0112 　 0.2464 0.0596 0.0346 0.0244 0.0168 0.0112 
　 　 　 0.75 0.1286 0.0396 0.0236 0.0168 0.0116 0.0078 　 0.1406 0.0404 0.0238 0.0168 0.0118 0.0078 
　 　 　 0.80 0.0918 0.0290 0.0172 0.0124 0.0086 0.0058 　 0.0966 0.0294 0.0174 0.0124 0.0086 0.0058 
　 　 　 0.85 0.0692 0.0222 0.0132 0.0094 0.0066 0.0044 　 0.0716 0.0224 0.0134 0.0096 0.0066 0.0044 
　 　 　 0.90 0.0542 0.0176 0.0106 0.0076 0.0052 0.0036 　 0.0554 0.0176 0.0106 0.0076 0.0052 0.0036 
　 0.3 0.2 0.30 　 　 0.2810 0.1786 0.1178 0.0756 　 　 　 　 0.2452 0.1346 0.0812 
　 　 　 0.35 　 0.1512 0.0846 0.0592 0.0408 0.0270 　 　 0.1728 0.0896 0.0614 0.0418 0.0274 
　 　 　 0.40 0.3026 0.0722 0.0422 0.0298 0.0208 0.0138 　 　 0.0750 0.0430 0.0302 0.0210 0.0138 
　 　 　 0.45 0.1472 0.0428 0.0254 0.0180 0.0126 0.0084 　 0.1622 0.0436 0.0256 0.0182 0.0126 0.0084 
　 　 　 0.50 0.0918 0.0286 0.0170 0.0122 0.0084 0.0056 　 0.0958 0.0288 0.0170 0.0122 0.0086 0.0056 
　 　 0.4 0.50   　 　 　 0.2708 0.1604  　 　 　 　 　 　 　
　 　 　 0.55 　 0.2420 0.1292 0.0890 0.0608 0.0398 　 　 　 0.1644 0.1012 0.0656 0.0418 
　 　 　 0.60 0.4542 0.0962 0.0558 0.0392 0.0272 0.0180 　 　 0.1064 0.0586 0.0406 0.0278 0.0184 
　 　 　 0.65 0.1798 0.0530 0.0314 0.0222 0.0154 0.0104 　 0.2260 0.0552 0.0320 0.0226 0.0156 0.0104 
　 　 　 0.70 0.1082 0.0338 0.0200 0.0144 0.0100 0.0066 　 0.1172 0.0344 0.0204 0.0144 0.0100 0.0068 
　 　 　 0.75 0.0734 0.0234 0.0140 0.0100 0.0070 0.0048 　 0.0766 0.0238 0.0142 0.0100 0.0070 0.0048 
　 　 　 0.80 0.0532 0.0172 0.0104 0.0074 0.0052 0.0034 　 0.0546 0.0174 0.0104 0.0074 0.0052 0.0036 
　 　 　 0.85 0.0404 0.0132 0.0080 0.0058 0.0040 0.0028 　 0.0412 0.0134 0.0080 0.0058 0.0040 0.0028 
　 　 　 0.90 0.0318 0.0106 0.0064 0.0046 0.0032 0.0022 　 0.0324 0.0106 0.0064 0.0046 0.0032 0.0022 
　 0.35 0.2 0.30 　 0.2472 0.1266 0.0870 0.0594 0.0390 　 　 　 0.1474 0.0948 0.0628 0.0402 
　 　 　 0.35 0.3726 0.0748 0.0434 0.0308 0.0214 0.0142 　 　 0.0786 0.0446 0.0312 0.0216 0.0144 
　 　 　 0.40 0.1308 0.0372 0.0220 0.0158 0.0110 0.0074 　 0.1448 0.0380 0.0224 0.0158 0.0110 0.0074 
　 　 　 0.45 0.0726 0.0224 0.0134 0.0096 0.0068 0.0046 　 0.0754 0.0226 0.0134 0.0096 0.0068 0.0046 
　 　 　 0.50 0.0468 0.0150 0.0090 0.0064 0.0046 0.0030 　 0.0478 0.0152 0.0090 0.0064 0.0046 0.0030 
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

or

　
∆
　
∆
 :  ≥ 　　 　  :  ≥　　
100 300 500 700 1000 1500 　 100 300 500 700 1000 1500
　 　 0.4 0.50   　 　 0.2970  0.1876  0.1234  0.0790  　 　 　 　 　 　 0.0984  
　 　 　 0.55 　 0.1128 0.0648 0.0456 0.0316 0.0208 　 　 0.1358 0.0704 0.0482 0.0328 0.0214 
　 　 　 0.60 0.1654 0.0490 0.0290 0.0206 0.0144 0.0096 　 0.2162 0.0512 0.0298 0.0210 0.0146 0.0096 
　 　 　 0.65 0.0874 0.0276 0.0164 0.0118 0.0082 0.0056 　 0.0938 0.0282 0.0166 0.0118 0.0082 0.0056 
　 　 　 0.70 0.0548 0.0178 0.0106 0.0076 0.0054 0.0036 　 0.0568 0.0180 0.0108 0.0076 0.0054 0.0036 
　 　 　 0.75 0.0378 0.0124 0.0074 0.0054 0.0038 0.0026 　 0.0386 0.0124 0.0074 0.0054 0.0038 0.0026 
　 　 　 0.80 0.0278 0.0092 0.0056 0.0040 0.0028 0.0020 　 0.0280 0.0092 0.0056 0.0040 0.0028 0.0020 
　 　 　 0.85 0.0212 0.0070 0.0042 0.0030 0.0022 0.0014 　 0.0214 0.0070 0.0042 0.0030 0.0022 0.0014 
　 　 　 0.90 0.0168 0.0056 0.0034 0.0024 0.0018 0.0012 　 0.0168 0.0056 0.0034 0.0024 0.0018 0.0012 
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1) Scatter plot of  vs  2) Scatter plot of  vs 
Appendix F : Figure A1. Scatter plot of the regional type II error rate and  with changes in  when  
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1) Scatter plot of  vs  2) Scatter plot of  vs 
- 96 -
1) Scatter plot of  vs  2) Scatter plot of  vs 
Figure A2. Scatter plot of the regional type II error rate and  with changes in  when 
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1) Scatter plot of  vs  2) Scatter plot of  vs 
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Appendix G : Relationship between the regional type I error and the 
assurance probability
          ∆∆ ≥
        ≥       ∆∆ ≥
        ≥



      
        ≥





∆∆   
  

∆∆
    if ∆ ∆ ,
        ≥






  
  
 
        ≥



     
    
      ∵


      
   
 ≥  
       
   where  



,     ,   ,
     ,  
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Similarly,
         ∆∆≥
        ≥      ∆∆≥
        ≥

        
        ≥




∆


∆
    



∆∆
    if ∆ ∆ ,
        ≥






 
   
 
        ≥



  
   
    ∵

 
      
   
 ≥  
       
  where  

,  

 ,  
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Appendix H : R program for calculating the regional type II error rate
(i) R program code for  calculation
rm(list=ls())
alpha<-0.025
effsz_1<-seq(0.1,1.5,0.1)
len.effsz_1<-length(effsz_1)
effsz_1c<-seq(0.1,1.5,0.1)
len.effsz_1c<-length(effsz_1c)
N<-seq(100,1000,100)
len.N<-length(N)
rho<-seq(0.5,0.9,0.1)
len.rho<-length(rho)
p1<-seq(0.05,0.95,0.05)
len.p1<-length(p1)
output<-matrix(NA,ncol=16,nrow=(len.effsz_1)*(len.effsz_1c)*(len.N)*(len.rho)*(le
n.p1))
colnames(output)<-c("Effect_size_1", "Effect_size_1c", "Alpha", "N", "P1", "Rho", 
"D1", "D2", "D3", "D4", "D5", "B1", "Numerator", "Denominator", "Output_NO", 
"Beta_1s") 
output
for(i in 1:len.effsz_1){
for(j in 1:len.effsz_1c){
  for(k in 1:len.N){
   for(l in 1:len.rho){
    for(m in 1:len.p1){
     d1=rho[l]*sqrt(p1[m]/(1-p1[m]))
     d2=sqrt(p1[m])/sqrt(2/N[k])*(rho[l]*effsz_1c[j]-effsz_1[i])
     d3=sqrt(p1[m])
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     d4=sqrt(1-p1[m])
     d5=qnorm(1-alpha)-(1/sqrt(2/N[k]))*(p1[m] * effsz_1[i] 
        +(1-p1[m])*effsz_1c[j])
     b1=d2+d1*(d5-d2*d3)/(d1*d3+d4)
     f1=function(u){
        y=(pnorm((u-d2)/d1)-pnorm((d5-d3*u)/d4))*dnorm(u)
        return(y)
                  }
     f2=function(u){
        y=(1-pnorm((d5-d3*u)/d4))*dnorm(u)
        return(y)
                  }  
     num=integrate(f1,b1,Inf)[[1]]
     denom=integrate(f2,-Inf,Inf)[[1]]
     beta_1s=round(num/denom,4)
     outno<-m+len.p1*(l-1)+(len.p1*len.rho)*(k-1)
            +(len.p1*len.rho*len.N)*(j-1)    
            +(len.p1*len.rho*len.N*len.effsz_1c)*(i-1)
     output[outno,]<-c(effsz_1[i], effsz_1c[j], alpha, N[k], p1[m], rho[l], 
                    d1, d2, d3, d4, d5, b1, num, denom, outno, beta_1s)
    }
   } 
  }
}
}
output
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(ii) R program code for  calculation
rm(list=ls())
alpha<-0.025
effsz_1<-seq(0.1,1.5,0.1)
len.effsz_1<-length(effsz_1)
effsz_1c<-seq(0.1,1.5,0.1)
len.effsz_1c<-length(effsz_1c)
N<-seq(100,1000,100)
len.N<-length(N)
rho<-seq(0.5,0.9,0.1)
len.rho<-length(rho)
p1<-seq(0.05,0.95,0.05)
len.p1<-length(p1)
output<-matrix(NA,ncol=16,nrow=(len.effsz_1)*(len.effsz_1c)*(len.N)*(len.rho)*(le
n.p1))
colnames(output)<-c("Effect_size_1", "Effect_size_1c", "Alpha", "N", "P1", "Rho", 
"D6", "D7", "D8", "D9", "D10", "B2", "Numerator", "Denominator", "Output_NO", 
"Beta_2s") 
output
for(i in 1:len.effsz_1){
for(j in 1:len.effsz_1c){
  for(k in 1:len.N){
   for(l in 1:len.rho){
    for(m in 1:len.p1){
     d6=rho[l] * sqrt(p1[m]*(1-p1[m]))/(1-rho[l]*p1[m])
     d7=d6*effsz_1c[j]*sqrt(1-p1[m])/sqrt(2/N[k])-effsz_1[i]*sqrt(p1[m])
        /sqrt(2/N[k])
     d8=sqrt(p1[m])
     d9=sqrt(1-p1[m])
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     d10=qnorm(1-alpha)-p1[m]*effsz_1[i]/sqrt(2/N[k])
         -(1-p1[m])*effsz_1c[j]/sqrt(2/N[k])
     b2=d7 + d6*(d10 - d7*d8)/(d6*d8+d9)
     f1=function(u){
        y=(pnorm((u-d7)/d6)-pnorm((d10-d8*u)/d9))*dnorm(u)
        return(y)
                  }
     f2=function(u){
        y=(1-pnorm((d10-d8*u)/d9))*dnorm(u)
        return(y)
                  }  
     num=integrate(f1,b2,Inf)[[1]]
     denom=integrate(f2,-Inf,Inf)[[1]]
     beta_2s=round(num/denom,4)
            
     outno<-m+len.p1*(l-1)+(len.p1*len.rho)*(k-1)+(len.p1*len.rho*len.N)
            *(j-1)+(len.p1*len.rho*len.N*len.effsz_1c)*(i-1)
     output[outno,]<-c(effsz_1[i], effsz_1c[j], alpha, N[k], p1[m], rho[l], 
                   d6, d7, d8, d9, d10, b2, num, denom, outno, beta_2s)
    }
   } 
  }
}
}
output
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국 문 요 약
  다지역 임상시험은 다양한 지역에서 동일한 계획서를 가지고 진행함으로써 모
든 지역에서 의약품 허가 및 등록을 용이하기 할 뿐만 아니라 각 지역에서 유사
한 임상시험을 중복하여 수행하지 않음으로써 시간과 비용을 줄일 수 있는 기회
를 제공하기 때문에 그 관심도가 지속적으로 증가하고 있다. 다지역 임상시험의 
목적을 달성할 수 있는 능력은 전체 치료 효과를 입증한 이후 참역한 개별 지역
에서 효과가 얼마나 유사한지에 달려 있다. 하지만 치료 효과의 지역 간 유사성
을 보이기 위한 유사성 기준에 대한 정의와 이러한 유사성을 보이기 위한 특정 
관심 지역에 필요한 임상시험 대상자 산출에 대한 기준에 대한 정의가 이뤄지지 
않고 있다. 2007년 일본 후생성은 다지역 임상시험에서 유사성 기준과 이러한 
기준을 근거로 일본에 필요한 임상시험 대상자수 산출에 대해 가이드라인을 제
공하고 있으나, 통계적인 관점에서는 제안하고 있지는 않다. 
  Ko et al.(2010)은 후생성의 가이드라인을 기반으로 보장 확률개념을 도입하
여 특정 관심 지역의 임상시험 대상자수 결정에 대해 제안했다. 하지만 다지역 
임상시험의 두 번째 목적인 지역 간 치료 효과의 유사성 대한 가설에 중점을 두
고 평가하지 않았다는 점에서 적절하지 않다. 본 논문에서는 다지역 임상시험의 
두 번째 목적을 통계적 가설 검정 절차로 활용한 Kang et al.(2016)의 방법을 
효과 크기로 표준화 하여 소개하였다. 또한 제안된 방법을 통하여 유사성에 대
한 가설 검정 위한 임계값 및 특정 관심지역에 할당되어야 하는 임상시험 대상
자수를 산출하기 위해 지역 제 2종 오류율을 활용하는 방법에 대해 논의 및 비
교 평가 하였다.
  유사성 기준에 따라 지역 제 2종 오류율을 계산하여 살펴본 결과, 특정 관심
지역의 효과 크기와 해당지역을 제외한 나머지 지역의 효과크기의 차이가 크거
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나, 유사성에 대한 임계값이 커질수록 지역 제 2종 오류율이 더 잘 조정 되는 
것 알 수 있다. 사전 정해진 수준의 지역 제 2종 오류율을 만족하면서 효과크기 
및 해당 관심 지역의 환자 할당 비율 등과 같은 모수가 동일하다면, 유사성 기
준  ≥  의 임계값이 유사성 기준  ≥  의 임계값 더 보수적이라고 
할 수 있다. 특정 관심 지역의 환자 비율의 경우 지역 제 2종 오류율과 단조 감
소의 형태를 보이지 않는다. 이러한 바람직하지 않은 특성은 새로운 유사성 기
준의 개발을 통해 개선이 필요하겠다. 또한 지역 제 1종 오류율을 조절하는 방
법은 Ko et al.(2010)의 방법의 확장된 형태로 지역 간의 치료 효과가 이질적이
라는 가정에서도 활용할 수 있다는 것을 확인 할 수 있었다.
  최근 우리나라도 다지역 임상시험을 통해 새로운 의약품을 개발하는 글로벌 
화 추세가 더욱 활성화되고 있다. 이렇게 다지역 임상시험의 수행 빈도가 높아
질수록 특정 관심 지역 예를 들어 우리나라에 할당되어야하는 임상시험 대상자 
수 산출 및 치료 효과의 민족 간 유사성을 평가하기 위한 임계값 설정이 더욱 
중요해 질 수밖에 없다. 이러한 임상개발 환경에서 본 논문에 소개된 지역 제 2
종 오류를 이용한 방법은 다지역 임상시험 환경에 유용하게 활용 될 것이며, 후
속 연구를 통해 개선된 방법을 개발 할 필요가 있겠다.
